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Abstract 
Cytotoxic chemotherapy is extremely important in adjuvant treatment of breast cancer. 
Yet, tumours frequently acquire chemoresistance that correlates with increased 
aggressiveness and poor prognosis.  Three theories exist describing how the resistance 
develops: genetic, epigenetic and karyotypic theory.  The epigenetic theory is the least 
explored. Here we analyzed the role of the epigenetic phenomena in the acquisition of 
drug resistance. To do so, we employed genome wide screens of microRNA and gene 
expression, DNA methylation and complete genome hybridization.  We identified three 
novel microRNA interactions involved in the chemoresistant phenotype.  These three 
microRNAs displayed depressed expression in the resistant cell lines and we were able to 
re-establish some level of drug sensitivity through ectopic expression of these under 
expressed microRNAs.    In addition, we described the role of DNA methylation in 
impacting expression of a wide range of genes, thus, contributing to the phenotype of 
chemoresistance.  Furthermore, we revealed a distorted global DNA methylation pattern 
that coincides with massive instability of the resistant genome.  Finally, our results 
present a striking similarity between gene expression, epigenetic profiles and 
chromosomal aberrations in two different drug resistant cell lines.  Taken together, this 
project suggests that the acquisition of chemoresistant phenotype is epigenetic in nature 
and may arise with a predictable pattern.  Elucidating the specifics of this pattern may in 
the future prove useful in developing treatment and prognostic chemoresistance 
biomarkers. 
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1.  General Introduction 
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1.1 Epidemiology 
At 28% of all new cancers, breast cancer is the most common and the second deadliest 
(15%).  With the exception of lung cancer, it is the only cancer type that has increased in 
incidence over the last 35 years
2
.  Furthermore, it is expensive to treat, with total 
treatment expenditures nearing $14 billion in 2006—the most expensive of any single 
cancer (NIH Cancer Trends Report, 2010).  Unfortunately, breast treatment does not pose 
a onetime challenge as ~30% of remised patients will endure recurrences which are 
predominantly metastatic and resistant to treatment and, thus, present a dismal outcome.   
1.2  Cancer Treatment 
Cancerous tumours are treated by surgical removal (resection), radiation exposure and 
chemical treatment (chemotherapy) or a combination of the three as dictated by cancer 
type, tumour size and location (NIH, 2010).  Since tumour masses originate from a single 
cell, it is important to eradicate all cells of an existing tumour to prevent recurrence.  This 
goal is severely hindered in resistant tumours as typically a reduced response is seen 
following both chemotherapeutic and radiation regimes.  Although the exact mechanisms 
are not yet understood, the newly acquired resistance (both chemical/drug and radio-
resistant) appears to coincide with increased invasiveness
3,4
.   
1.2.1 Chemotherapy  
The use of chemotherapy as a strategy to treat cancer emerged in the 1940‘s.  The first 
example of its use in clinical practice involved the treatment of a malignant lymphoma 
with nitrogen mustard; achieving a regression in the disease.  However, a second dose 
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elicited a lesser affect and a third led to no response at all
5
.  So, for as long as 
chemotherapy has been employed, acquired drug resistance has followed.   
The goal of chemotherapeutic agents is cytotoxicity.  Usually this is achieved through 
interfering with key life processes including DNA replication and repair or mitosis.  
However, in the last few decades several drugs that facilitate the cytotoxic effects by 
repressing growth signals or promoting apoptosis have been designed and licensed (NIH, 
2010).  At current, chemotherapeutic agents fall into six categories: i) direct DNA 
damaging agents; ii) anti-metabolites that prevent viable DNA/RNA production (e.g. 
nucleoside analogs); iii) DNA intercalators that interfere with replication machinery; iv) 
topoisomerase inhibitors that prevent the proper management of replication forks; v) anti 
mitotic agents that prevent cytokinesis, and; vi) targeted therapies that are engineered for 
specific targets in specific tumour types or towards the tumour microenvironment (NIH, 
2010).  Instances of resistance have been described for drugs in each category
6
. 
1.2.1.1  Cisplatin and Doxorubicin 
Cisplatin and doxorubicin belong to the DNA damaging and DNA intercalating 
categories; respectively, as such they are considered genotoxic agents.  Both of these 
drugs function at the level of replication. Cisplatin, an alkylating agent, belongs to the 
platinum-based drug class and was developed over 30 years ago.  It is a neutral, planar 
molecule that requires activation via two aquation reactions upon entry into the cell.  In 
its active form, cisplatin causes bulky, intrastrand, cross linked adducts between adjacent 
purine residues
7
.  The slightly older (developed ~50 years ago) anthracycline, 
doxorubicin—a large planar molecule with several aromatic rings, intercalate into DNA 
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strands by positioning itself between base pairs and the minor groove of the DNA 
backbone.  When in position, it is capable of impeding transcriptional and replication 
machinery
8
.  These adducts, if left unrepaired, stall the machinery preventing proper 
replication and ultimately invoke an apoptotic signal through the DNA damage signalling 
pathway
7,8
.  Both drugs are amongst the widest prescribed and most effective, however, 
acquired resistance is frequently observed in treated patients.  For example, ovarian 
cancer initially responds favourably about 70% of the time to cisplatin, however, 5-year 
survival rates are ~15-20% as resistance is acquired to a broad range of drugs
7
.  Although 
doxorubicin is among the most active agents in breast cancer treatment, many women 
will experience a relapse.  Furthermore, approximately half of women with metastatic 
breast cancer will fail to respond to doxorubicin, and the majority of those showing initial 
benefit will subsequently deomstrate acquired clinical resistance, as demonstrated by 
tumor growth despite ongoing antracycline treatment
9
.     
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1.3 Molecular Mechanism of Drug Resistance 
The main goal of chemotherapy is to impart a cytotoxic effect on tumour cells.  In short, 
this relies on three critical points: i) drug uptake; ii) interaction with target, and; iii) 
induction of apoptosis.  Although the preceding sentence greatly oversimplifies the 
complexities of each step, it demonstrates that there are a finite number of opportunities 
by which a cancer cell may evade the effects of a drug.  From a molecular perspective, 
this evasion is achieved through: i) reduced intra-cellular concentrations (impaired 
uptake; increased efflux); ii) increased or altered targets, drug inactivation or drug 
compartmentalization, and; iii) evasion of apoptosis via altered checkpoints or repairing 
DNA damage
1,6
 (Figure 1.1)   
1.3.1  Drug Uptake 
The first important hurdle in achieving an effective drug response, is delivery to the cell.  
Congruently, the first mechanism of resistance is achieved by hindering transport into or 
accumulation in the cell.  For example, resistance to methotrexate (MTX), an anti-
metabolite drug whose toxic effects are achieved through preventing nucleoside 
synthesis, is observed in leukemia patients.  MTX enters the cells through a solute carrier 
membrane protein.  Reduced expression of this transport protein is associated with 
increased MTX resistance in cell lines and tumours and poor patient prognosis
10-12
.  
Besides import proteins, reduced accumulation can be the result of increased efflux.  
Drug efflux pumps are large transmembrane proteins that actively transport molecules 
across the membrane
13
.  Although these transporters serve important physiological 
functions such as moving xenobiotics in a unidirectional fashion, protecting cells from 
toxic species and concentrating metabolic products; over expression and activity is 
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frequently observed in resistant phenotypes of solid tumours and leukemia
6
. Furthermore, 
the broad specificity of substrates for these pumps can account for the multi-drug 
resistant phenotype.  The efflux pump most studied in a wide variety of cancers is aptly 
named multi-drug resistance-1 (MDR1). It can transport a wide range of neutral and 
positively charged hydrophobic drug species, including doxorubicin
14,15
.  Unfortunately, 
large scale cloning studies, demonstrated that many multi-drug resistant tumours did not 
express MDR1, however, they did express another member of the efflux family known as 
multi-drug resistance associated protein-1 (MRP1).  Although MRP1 functions in the 
same manner as MDR1, it has a preference for negatively charged drugs including 
conjugated-cisplatin
1
 and MRP1 is known to play a role in cisplatin resistance
7,16,17
. 
1.3.2  Interaction with target  
 1.3.2.1  Drug Inactivation 
Drug metabolism circumvents the cytotoxic nature of a drug typically by reducing 
availability of free drug to interact with its target.  5-fluorouracil, a nucleoside analog that 
is frequently prescribed for solid tumours, is catabolised and inactivated by the cytosolic 
enzyme dihydropyrimidine dehydrogenase (DHD).  Over expression of DHD both in 
vitro and in vivo is linked to 5-fluorouracil resistance
18,19
.  Although this represents an 
outright destruction, more subtle modifications can still manage to impact the efficacy of 
a drug. Cisplatin is known to be modified by the cytosolic, scavenging, antioxidant 
glutathione (GSH).  In the presence of glutathione-S-transferase (GST), cisplatin is 
covalently linked to GSH.  This conjugated form is a better substrate for the MRP1 pump 
than cisplatin alone and, thus, is shuttled out of the cell.  High levels of GST and GSH 
7 
 
expression are linked to cisplatin resistance
20,21
.  Furthermore, repression of GST has 
reversed cisplatin resistance in breast cancer cells
22
.  
 1.3.2.2  Altered Targets 
Mutated drug targets or their over expression can impact the efficacy of a drug.  For 
example, the expression levels of thymidine synthase (TS), the target of 5-fluorouracil, 
regulates chemosensitivity.  Patients exhibiting an activating polymorphism in the 
promoter region of thymidine synthase over express TS and demonstrate resistance to the 
drug
23
.  In another instance, decreased topoisomerase II activity due to reduced protein or 
mutations in the gene, confers resistance to doxorubicin
24,25
.  Finally, resistance to 
taxanes, drugs that act on the microtubule dynamics, has been observed in patients that 
display altered microtubule mass or express different tubule isotypes
26,27
.   
1.3.3 Induction of apoptosis  
Apoptosis is mediated through several interconnecting pathways and a multitude of 
proteins including, those employed in the DNA damage response, cell cycle, intrinsic 
apoptotic and proliferative pathway.  For ease of presentation, these pathways are 
addressed below independently, however, it is impossible to expect changes in one of the 
pathways to not heavily influence the activity of the other three.   
 1.3.3.1  Repairing DNA damage 
Many chemotherapeutic regimes attempt to induce massive DNA damage, either directly 
(e.g. alkylating agent-cisplatin) or indirectly (e.g. stalling replication/translational 
machinery- doxorubicin).  If plentiful enough, this damage should induce apoptosis.  
However, in some instances, the over expression of DNA repair genes can efficiently 
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reverse any acquired damage.  For example, cisplatin causes intra-strand adducts between 
adjacent purines that are readily reversed by the nucleotide excision repair pathway.  
Although this is an intricate pathway that involves in a multitude of different genes, over 
expression of the few rate-limiting players is sufficient to induce cisplatin resistance.  
ERCC1 and XPA over expression, both involved in the excision of the damaged strand, 
correlate well with cisplatin resistance in clinical samples of numerous tumour types
28,29
 .   
Interestingly, cases of resistance are reported in repair deficient cells as well.  Abrogated 
mismatch repair proteins MSH2 and MLH1 have been implicated in the acquired 
resistance of ovarian tumours and cells to both cisplatin and doxorubicin
30-32
.  This loss 
of MMR was linked to DNA methylation and microsatellite instability (two epigenetic 
features; explained elsewhere)
33,34
.  Furthermore, the loss of MMR coincided with 
increased translesion synthesis, suggesting a plausible mechanism which allows these 
resistant cells to evade death
35
.   
1.3.3.2  Altered Checkpoints 
Cells employ an elaborate system of checks and balances, termed cell cycle checkpoints, 
to ensure that genetic integrity is maintained between generations.  In the event that it is 
not, a normal cell will induce apoptosis over proliferation.  Circumventing any of these 
checkpoints can shift this balance.  The master switch between DNA damage detection, 
cell cycle arrest and apoptosis is the p53 protein.  Indeed, its importance is illustrated by 
the observation that p53 is mutated in up to 50% of cancers.  However, it appears that 
p53 gene mutations do not correlate with expression in 30-40% of cases
6
.   
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Conflicting reports also exist about its role in drug resistance.  For example, opposing 
outcomes (sensitising and desensitizing) have been reported on the effect of p53 
mutations in cisplatin treated cells (in vitro)
36,37
.  From a molecular perspective it is also 
difficult to deduce the effects of p53 on resistance.  On one hand a lack of p53 may 
prevent a cell from inducing apoptosis while on the other hand, WT or increased 
expression may increase the amount of time for DNA repair during cell cycle arrest: 
either way both result in a resistant phenotype.  Furthermore, some studies indicate that it 
is unclear whether p53 status indicates poor prognosis due to platinum-base drug 
resistance proper or rather due to the increased aggressiveness seen in several resistant 
tumour types
38
.  These conflicting results are observed in other genome damaging drugs 
as well such as 5-fluorouracil.  Interestingly, doxorubicin seems to have a more 
predictable outcome: its sensitivity is dependent upon a WT p53 function with mutated 
and null p53 leading to resistance
39
.   
 1.3.3.3  Apoptotic Pathway 
Apoptosis is the death of a cell through a purposeful, mechanistic dismantling of the 
cellular machinery.  It is induced through a number of signalling molecules with the most 
proximal being the Bcl-2 family of proteins.  This family includes both pro-apoptotic 
(Bad, Bak and Bax) and anti-apoptotic members (Bcl-2, Bcl-xl and Mcl-1).  Not 
surprisingly, there is good correlation between the expression levels of the Bcl-2 family 
of proteins and response to a wide range of chemotherapeutic agents.  Specifically, down 
regulation of the anti-apoptotic members Bcl-2 and Bcl-xl (in vitro) increases sensitivity 
to a platinum drug, while loss of pro-apoptotic Bax decreases sensitivity
40
.  Likewise, 
over expression of Bax in breast cancer cells increased sensitivity to cisplatin and 
10 
 
radiation, thus, providing some explanation of the cross resistance mechanism
41,42
.  Once 
again, the status of Bcl-2 family members does not appear to be universal as others have 
reported a relationship between high Bcl-2 expression and increased sensitivity.  In this 
instance, it has been suggested that the grade and aggressiveness may affect the death 
potential of the apoptotic proteins, with lower grade and less aggressive tumours 
responding to treatment regardless of Bcl-2 status
43
.   
 1.3.3.4 Proliferative Signals 
As mentioned above, the proliferative pathway interacts directly with the apoptotic, cell 
cycle, and DNA damage pathways.  Built into proliferative pathways are proteins capable 
of inhibiting apoptotic signals.  One such protein is Akt, an intracellular ser/thr kinase 
involved in the EGF pathway.  Akt gains its anti-proliferative properties by inhibiting the 
pro-apoptotic proteins Bad and Casp9 and promoting NFκB.  NFκB in turn promotes the 
pro-apoptotic Bcl2/Bcl-xl and ‗inhibitor of apoptosis proteins‘.  Inhibiting the activity of 
AKT or NFκB was shown to increase sensitivity to several drugs and radiation therapy44-
47
. 
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  1.4  Theories of drug resistance 
Although the molecular and cellular characteristics of drug resistance are frequently 
observed and explored, there is less information on how cells acquire these molecular 
changes in the first place.  Several theories have been described.  They will be detailed 
below.    
1.4.1  Development of Resistance 
As mentioned before, numerous cellular pathways have been inlcated in drug reistance. 
Yet, why and how are these pathways affected? As an added difficulty, tumours often 
demonstrate cross-resistance to an array of drugs that may be chemically different or 
even to other cytotoxic  treatments i.e. radiation therapy.  Boehm and Hahn attempted to 
evaluate the minimal and necessary mechanism that could elicit a drug resistant 
phenotype.  They found that by introducing a number of transgenic mutations in a 
stepwise fashion they could create a tumorgenic cell.  These mutations involved 
maintaining telomere length (increased telomerase activity), diminishing cell cycle 
control (p53 and RB inactivation) and promoting aberrant signalling (PP2 inactivation; 
constitutive Ras activity) and were performed in several primary epithelial cells including 
mammary gland, prostate, ovary, trachea and bronchia.  Interestingly, with the exception 
of the post-telomerase mutation, treatment of these transformed cells following each step 
with doxorubicin demonstrated a drug-resistant phenotype
48
.  This model revealed that 
the acquisition of drug resistance likely occurs through a mechanism similar to that of 
malignant transformation.  However, it should be noted that not all naturally occurring 
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tumours exhibit the aforementioned marks and, thus, just as tumorgenesis involves a 
multi-faceted mechanism, so does the acquisition of drug resistance
49
.   
Through rapid Darwinian evolution and clonal expansion, resistant cells experience 
positive selection and, ultimately, will increase their frequency in the tumour cell 
population.  When combined with the high proliferative rate observed in tumours, the 
acquisition of a resistant phenotype for the tumour as a whole becomes a relatively quick 
process.  With the heterogenic nature of tumours, the degree of resistance can vary within 
a single tumour
50
.  Iwasa et al. have managed to mathematically model the acquisition of 
resistance and not surprisingly they noted that probability of acquiring resistance 
increases with higher proliferative rates and increased genomic instability
51
.  
The clinical endpoint referred to as drug resistance is usually a multi-faceted 
characteristic resulting from a several different events within a single cell. Delineating 
the underlying mechanism and attempting to circumvent it is a daunting, yet necessary, 
task since drug resistance diminishes treatment efficacy in 90% of cancer cases and 
nearly all recurring cancers are resistant and metastatic
6
.  The phenomenon of 
chemotherapeutic drug resistance has been observed since the first use of chemotherapy 
as an anti-cancer agent
5
.  Several models attempt to explain the acquisition of drug 
resistance.  These include the genetic, epigenetic and karyotypic theories.  The genetic 
theory attempts to explain resistance through acquisition of mutations that impart an 
added fitness to the cells.  This fitness is qualified through increased resistance to the 
chemotherapeutic regime.  Conversely, epigenetics implicates non-mutational alterations 
that impact gene function (DNA methylation, histone changes and/or small, non-coding 
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RNA regulation) as the driving force behind the resistant phenotype.  Finally, the 
karyotypic theory aims to illustrate the role of massive chromosomal aberrations and/or 
aneuploidy in the generation of the novel drug resistant phenotype
52
.  Although evidence 
supporting each of the three theories exists, it is unlikely that any one of the three can 
solely explain the phenomenon: they likely all play some role but to varying extents.   
 1.4.1.1 Genetic Theory  
Genetic mutation is thought to be a hallmark of the carcinogenesis process.  The 
relationship between mutations and tumorgenesis describes a scenario where an initial 
mutation causes a phenotype that promotes and permits subsequent mutation events: over 
time this process culminates in cancer as, together, these mutations impact a number of 
cellular functions including apoptosis, cell cycle control, DNA repair, proliferation, 
invasiveness and transcription; for example.  Large scale studies have: a) confirmed a 
high mutation rate in tumour cells, and; b) demonstrated a lack of similarity in mutation 
profiles between various tumour-types or within cells of the same tumour
53
.  Therefore, it 
seems reasonable to expect that some of these mutations may impact the sensitivity of the 
cell.  This premise is further bolstered by the observation that the acquisition of drug 
resistance can occur concurrently with carcinogenesis and it is only following initial 
rounds of treatment, which removes sensitive cells, that the resistant cells flourish giving 
rise to a new, resistant tumour mass
5
.   
In a well documented example of resistance, dozens of mutations interfering with drug-
target interactions have been characterized in BCR-ABL kinase: the cellular protein 
target of imatinib (a targeted chemotherapy regime).  These mutations, however, were not 
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―acquired‖ following initiation of the treatment, but rather existed in a subset of tumour 
cells and were selected for during the treatment
54-56
.  In another instance, patients with 
non-small cell lung cancer display resistance to the EGFR antagonists gefitinib and 
erlotinib through mutations in EGFR or k-Ras gene (an early member of the EGFR-
induced signally pathway)
57,58
. However, the narrow scope of these drugs (one drug: one 
protein target) allows a cell to evade their cytotoxicity through mutations affecting a 
single gene.  Therefore, it doesn‘t explain multi-drug or cross-resistance which is usually 
the case.  Furthermore, an identified mutation in the coding sequence of a gene does not 
necessarily impact the structure, function or stability of the resulting protein and, thus, 
mutations identified in resistant tumours may apply little pressure on the drug-target 
interaction
59
.  Finally, one may speculate that multi-drug resistance can be the result of 
mutations in genes that have a global impact on the cell.  For example, mutations in p53 
coincide with resistance to many cytotoxic drugs, and p53 status is important in 
determining a prognosis for responsiveness to platinum based chemotherapies
60-62
.  
However, these p53 mutations/status were innate properties of the tumour cells that 
existed prior to treatment and, thus, do not explain acquired drug resistance observed 
during the course of treatments or in secondary cancers
63
. 
Another blow to the genetic theory arises from the observation that cells gain resistance 
at rates higher than the mutational rate.  Spontaneous resistant rates are approximately 
10
4
 to 10
11
 fold higher in tumour cells under selection pressure than the mutational rate 
(10
-7
 and 10
-14
, for mono-allelic and bi-allelic genes per cell generation, respectively) 
and, therefore, at best mutation could only account for ~1 in every 10
4
 resistant cells
52
.  
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Thus, it is necessary to develop a theory that can account for a larger number and wider 
range of gene changes.            
 1.4.1.2  Epigenetic Theory 
Because mutations are either: impotent at affecting a large enough change in protein 
structure, function or stability to allow for altered drug interactions; or, cause such 
specific changes to a narrow niche of the cell that many characteristics of the drug 
resistant phenotype remain unexplained, the genetic theory is insufficient in explaining 
drug resistance.  Resistance is more likely the result of alterations in expression of 
multiple genes in varied pathways and a feasible model must address this scenario.  The 
epigenetic theory works toward this ends
63
.  Epigenetic modifications such as DNA 
methylation, histone modifications and small, non-coding RNA regulations can have a 
large impact of gene expression.  Although epigenetics does not necessarily explain 
aberrant function of a particular gene product, it can explain dysregulated pathways and 
distorted expression patterns.  Furthermore, it has the potential to impact a multitude of 
genes concurrently—a necessary characteristic in explaining drug resistance.  Like 
genetic mutations, epigenetic alterations are stable, heritable changes that are propagated 
in clonal fashion and, thus, can explain subpopulations of resistant cells stemming from 
an initially resistant tumour.  Perhaps the strongest suggestion that epigenetics may play a 
role in acquired drug resistance lies in the observation that cancer cells already 
demonstrate some degree of epigenetic dysregulation.  They are known to be globally 
hypomethylated with localized hypermethylation at particular gene promoters and display 
aberrant silencing histone modifications.  Moreover, it has been shown that the cellular 
profiles for small, non-coding RNAs, microRNAs, are also drastically different
64,65
. 
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Therefore, it is plausible that epigenetic dysregulation may play a role in the acquisition 
of a drug resistant phenotype.  
Examples of epigenetic influences of drug resistance include silencing of pro-apoptotic 
genes and silencing of DNA repair genes.  Apaf1, an apoptosis activating factor, is 
heavily methylated in chemoresistant melanoma lines.  Since the end goal of all 
chemotherapeutic agents is to induce death, loss-of-function in any necessary member of 
the apoptotic pathway will manifest as a resistant phenotype.  The hypermethylation of 
the Apaf1 promoter silenced the activity of the gene and, thus, prevented apoptosis.  
Relief of Apaf1 repression and increasing sensitivity of the cells was observed following 
treatment with a demethylating agent, 5-azacytidine
66
.  In addition, DNA repair capacities 
can impact drug-sensitivity.  Many drugs, such as cisplatin, impart their effect by causing 
DNA damage that, if left unrepaired, is lethal
7
.  In one such example, methylation of the 
DNA repair gene MGMT that reverses the damage induced by DNA alkylating agents 
has been shown to be a strong prognostic tool for determining the treatment response of 
gliomas, i.e. methylated MGMT conferred sensitivity to the drugs
67
.  In another example, 
methylation of FANCF, a gene involved in regulating an S-phase/G2 arrest checkpoint, is 
responsible for cisplatin sensitivity in ovarian cells.  Demethylation of the FANCF 
promoter coincided with the acquisition of cisplatin resistance
68
.  Although, at current, no 
specific examples linking particular histone modifications to a drug resistant phenotype 
have been described, the fact that DNA methylation and histone modifications usually 
occur together, suggests they likely play a role in silencing or permitting expression of 
key genes
69
. 
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It has been noted that altered miRNA expression in cancer cells coincides with altered 
drug metabolism in several human cells.  Specifically, Blower et al., found that of the 31 
miRNAs that correlated with anti-cancer compound activity of 14 drugs, 10 were 
aberrantly over expressed in several cancer tumour types.  One of these, miRNA21, was 
able to significantly impact the efficacy of six of the 14 drugs tested between 2 and 4-
fold—it increased sensitivity in two cases and increased resistance in four70.  Since a 
single miRNA has the potential to target hundreds of transcripts, it is rather unremarkable 
that miRNA 21 impacted the efficacy of six different drugs.  However, it is not clear what 
targeted transcripts and the resulting reduction or increase in their translation imparted 
this effect.     
Where the one mutation: one affected target of the genetic theory falls short in describing 
the polygenic nature of resistance, the wide reaching impact of miRNAs (and to a lesser 
extent DNA methylation) damage the epigenetic theory.  That is, it is possible that the 
wide sweeping effects of ‗epimutations‘ likely impact so many aspects of the cellular 
function, that is in only a few cases that cells acquire an advantageous mutation that 
results in drug resistance.  For example, Luhzna et al. recently demonstrated that the 
cross resistance to radiation observed in a doxorubicin resistant breast cancer line could 
be sensitized in the presence of SAM, a methyl donor for the DNA methylation event.  
However, SAM treatment of the already sensitive parental line results in the acquisition 
of radio-resistance.  Therefore, it appears that DNA methylation (and perhaps other the 
epigenetic regulators) needs to be precisely modulated to achieve a favourable effect
71
.   
It will be necessary to explore the epigenetic profiles of multiple resistant cells to 
determine whether a common profile exists.        
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 1.4.1.3  Karyotypic Theory 
The karyotypic theory implicates gross chromosomal alterations as the cause of acquired 
drug resistance.  For example, just as trisomy 21 generates a new phenotype—Downs 
syndrome; aberrations in cancer cells can alter the stoichiometry and integrity of 
multigenic transcriptomes.  The karyotypic theory has foundation in the fact that existing 
cancer cells already demonstrate some degree of aneuploidy and, thus, experience 
chromosomal instability.  With the existing aneuploidy comes a misbalanced potential for 
synthesis, repair and mitotic segregation and the rate of chromosomal alterations is 
proportional to the degree of aneuploidy.  Similar to the genetic theory, the role of the 
karyotype is not inherent to the phenomenon of acquired drug resistance, but rather is a 
extension of the pre-existing characteristics of cancer cells
52
.          
Duesberg et al. have presented several compelling arguments to support the role of the 
karyotype in acquired drug resistance.  These include: i) karyotypic changes coincide 
with drug resistance; ii) the rate of the karyotypic changes is similar to the rate of 
spontaneous acquisition of drug resistance, and; iii) cells are usually multi-drug— and 
cross resistant and display other changes in quantifiable characteristics (e.g. morphology 
and invasiveness) necessitating an event capable of impacting numerous genes
52
.  
However, they do not speculate about the underlying mechanism of the pre-requisite 
aneuploidy.  Epigenetics is a plausible culprit.  Genome stability is maintained through 
the resistance and reversal of genetic changes including mutations, rearrangements and 
breaks and is mediated through the epigenetic mechanisms of DNA methylation and 
histone modifications (with a postulated role for small, non-coding RNAs).  Therefore, it 
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is likely that the chromosomal aberrations observed by Duesberg et al., (importantly) in 
the absence of any genotoxic agent, were dependent upon epigenetic mechanisms. 
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1.5  Epigenetic Regulation  
Most cellular mechanisms depend heavily on upon gene expression and organization, as 
well as on the accessibility of DNA in DNA-protein interactions. These domains are 
governed by epigenetic processes—meiotically heritable and mitotically stable alterations 
in gene expression.  Epigenetics includes DNA methylation and histone modifications 
with a recent addition of small, non-coding RNA regulation. It is important to note that 
these mechanisms are not mutually exclusive of each other and have an added 
responsibility of controlling genome stability
72
.     
1.5.1  DNA Methylation 
Mammalian DNA methylation has only been described as a covalent addition of a methyl 
group at the 5-carbon position of the cytosine base and it has a well investigated role in 
controlling gene expression, genetic imprinting, and tissue- or temporal- specific gene 
expression.  DNA methylation is a stable and heritable, yet reversible epigenetic trait of 
mammalian genomes
73,74
.  There are three main contributing proteins involved in 
establishing and maintaining DNA methylation patterns within mammalian cells: DNA 
methyltransferase (DNMT) 1, DNMT3a, and DNMT3b
75,76
.  DNMT3a and DNMT3b are 
responsible for de novo methylation of sequences and appear to hold an indispensable 
function, as mutant mice lacking either of these genes die within weeks of birth or are not 
viable through the embryonic stages; respectively.  Not surprisingly, DNMT3a and 
DNMT3b are extremely active during development where cellular differentiation is 
achieved through high levels of de novo DNA methylation in promoter regions of 
pluripotency genes
77,78
.  In contrast DNMT1 is responsible for restoring the methylation 
pattern on hemi-methylated DNA following replication. It is localized to the replication 
21 
 
fork, where it could directly modify nascent DNA immediately after replication 
73,75,79
.  
Its function is also mandatory as DMNT1-/- mice are embryonic lethal
80
.   
A correlation between methylation status and expression of endogenous genes is 
apparent
81
.  Cytosine methylation is observed at CpG dinucleotides that tend to cluster 
into islands containing >55% GC content over a 500 base region
73
.  These CpG islands 
are observed within the promoters of about ~72% of human genes and methylation of 
CpG-rich promoters frequently coincides with reduced gene activity
82
.  The reduced 
expression is achieved directly through disruption of the transcription factor and RNA 
polymerase binding as well as, indirectly, through the recruitment of methyl-CpG binding 
domain proteins as subsequent chromatin remodelling
83
 (the implications of which are to 
be discussed in the following section).     
 Besides controlling gene expression, DNA methylation is complicit in suppressing 
parasitic DNA sequences such as transposonable elements and endogenous retroviruses
84
.  
It is postulated that up to 35% of the human genome is composed of parasitic sequences 
and that most of them are methylated in an attempt to quarantine these sequences
85
.  
Active transposable elements are highly mutagenic as they tend to insert within expressed 
genes disrupting its normal function and can cause illegitimate recombination events and 
genomic rearrangements
86
.  Interestingly, global hypomethylation is a hallmark of all 
stages of tumour cells with a 20%-60% decrease in methylated cytosines.  This decrease 
in methylated DNA coincides with the reactivation of transposable elements, mitotic 
recombination (leading to loss of heterozygosity) and aneuploidy
73,87,88
.  Furthermore, 
cells lacking the activity of DNMT3b display high levels of chromosome aberrations
89
.  
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Therefore, in a hypomethylated environment chromosomal instability increases and 
genome integrity is challenged.   
1.5.2  Histone Modifications 
In the nucleus, eukaryotic DNA closely interacts with histones
72,87
.   Histones are structural 
proteins that provide scaffolding for DNA molecules to wrap around in a predictable 
manner forming many nucleosomes in a ‗beads-on-a-string‘ manner.  The nucleosome 
contains 4 core histones, H2A, H2B, H3 and H4 which exist in duplicate forming an 
octamer around which approximately 150 base pairs of DNA is wrapped
90
.  The most 
obvious role of the histones is to provide scaffolding for the DNA molecule—mechanical 
support that protects the linear DNA molecule from becoming tangled with other 
molecules or breaking during the movement experienced throughout the cell cycle.  In the 
last few decades, it has been discovered that histones are subject to numerous 
posttranslational modifications.  These modifications can affect their interactions with 
DNA and other proximal non-histone proteins. These modifications have a profound 
impact on transcriptional expression, DNA repair and genome stability
91,92
.  The 
combination of DNA wrapped around histones is referred to as chromatin and it generally 
falls into two categories: heterochromatin; a tightly wound, inaccessible state, or 
euchromatin, an open, accessible form.   
Post-translational modifications to the N-terminal ends of histones include 
phosphorylation, acetylation, methylation, sumolation and ubiquitination events that 
define and/or change the chromatin state.  Collectively, histone modifications are known 
as the histone code and constitute part of the epigenome of a given cell
91,93-95
.  Chromatin 
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remodelling frequently occurs to modify the transcriptional activity of a gene. It is 
achieved through the above mentioned post-translational modifications.  Unlike DNA 
methylation where a single chemical modification occurs at a single position on a single 
base, histone modifications are much more complex.  The general school of thought is 
that these chemical modifications on histones alters the shape of the chromatin, thus, 
affecting the ease with which non-histone proteins may access and bind, in turn altering 
the transcriptional outcome.  Histone modifications are achieved through the work of 
several different enzymes including histone methyltransferases, histone acetylases and 
histone deacetylases amongst others
91
.  
Histone modifications that are indicative of silencing commonly occur along with DNA 
methylation.  Furthermore, it was recently shown that tumours undergo a massive shift in 
the profile of their histone code
96,97
.  This loss occurs along with DNA hypomethylation 
and is linked to chromatin relaxation and aberrant expression. It was suggested to be a 
universal marker for malignant transformation and genome instability
96
.  Although it has 
been stipulated that one event may beget the other, evidence supporting which is the 
antecedent action waivers between the two. Furthermore, it is not obligatory to have 
DNA methylation changes that coincide with silencing histone modifications or vice 
versa
98
.   
Besides providing flexibility with expression levels, histone modifications play an 
important role in genomic stability.  Highly repetitive regions such as telomeres, 
centromeres and transposable elements can challenge genome integrity if the surrounding 
chromatin adopts a more relaxed state.  For example, the nature of telomeres (i.e. they are 
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basically a dsDNA break) make them good candidate for errant NHEJ and HR—events 
that would lead to gross chromosomal aberrations, aneuploidy and/or gene duplication
99
.  
Likewise, histone modifications work in conjunction with DNA methylation to maintain 
transposonable elements in a heterochromatic state.  In mouse models transposon  re-
activation was associated  with chromosomal segregation defects
86
.    
1.5.3  Small, non-coding RNA regulation 
Recently it has been discovered that small RNA molecules can act in a potent gene 
silencing mechanism that in mammalian cells involves the inhibition of translation.  This 
mechanism—post-transctriptional gene silencing (PTGS), involves a class of short (21-25 
nTs), non-coding RNA molecules.  These molecules are generated through a two-step 
cleavage of the long primary RNA transcript that forms secondary hairpin structures.  
The first cleavage is performed in the nucleus by the RNase III protein Drosha and results 
in a shortened hairpin that is transported to the cytoplasm where a second RNase III 
protein, Dicer, performs the second cleavage.  The Dicer-dependent cleavage results in 
short dsRNA molecules that are 19 to 23 base pairs in length.  These short dsRNA 
molecules are loaded onto a RNA-induced silencing complex (RISC) where they are 
further processed and matched with their complimentary sequence within the 3‘ 
untranslated region (UTR) of mRNA transcripts.  This mature, single stranded RNA 
molecule is termed a microRNA (miRNA).  Imperfect base pairing between the miRNA 
and a cognate 3‘UTR results in inhibition of the translational machinery and eventual 
sequestering and destruction of the messenger molecule
100
.  PTGS is a widely conserved 
mechanism for controlling gene expression across several kingdoms.  However, it is also 
employed in plants, fungi and some invertebrates as an effective mechanism for 
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achieving transcriptional gene silencing (TGS).  During TGS, transcribed dsRNA are 
cleaved into small perfectly matched molecules capable of guiding the acquisition of 
DNA methylation patterns and/or silencing histone modifications at their complimentary 
sequences: the result being a localized change in the epigenetic profile of that cell.  
Although no such mechanism has been described in somatic mammalian cells, there has 
been some evidence that this is possible
101-104
.  If true, this would incorporate small, non-
coding RNA regulation as a bona fide epigenetic mechanism. 
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1.6 Preliminary Data     
MCF-7 cells were exposed to increasing concentrations of the chemotherapeutic drugs 
cisplatin and doxorubicin; respectively.  The concentrations of the drugs were increased 
gradually from 0.5 to 15 μg/mL over a six month period.  The resulting cells LD50 was 
12μM and 94μM for the MCF7 and MCF7/CDDP  lines, respectively; and 1μM and 
24μM for the MCF7 and MCF7/DOX lines, respectively).  Besides increased tolerance 
for the drug, these cells demonstrated: increased resistance to radiation treatment, global 
hypomethylation and reduced background levels of apoptosis
21,71
.  Furthermore, no 
reversal of the resistant phenotype was observed following cessation of the drug 
treatment.  
Overall, from the literature and the preliminary data obtained by the Kovalchuk 
laboratory and our collaborators, we have learned that global, and some promoter-
specific, DNA methylation changes and global microRNAome alterations are important 
in breast cancer drug resistance. However, the vast majority of studies have analyzed 
either global genome changes which lack vital locus-specific details, or use a 
reductionist-type ‗pick-and-choose‘ approach to analyze genes and miRNAs.  Thus, there 
is still much to be learned regarding the exact details of epigenetic DNA methylation and 
microRNAome changes in drug resistant cells and the exact contributions of known 
epigenetic mechanisms on the development of drug resistance. Breast cancer cell lines 
representing the extremes of drug resistance constitute an excellent model system for 
initial epigenome mapping.  
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Therefore, I set out to establish an important and clinically relevant cell-line based -
‗inventory‘ of drug resistance-related epigenetic changes to form a solid basis for our 
future translational efforts. 
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1.7  Hypotheses 
Rationale 
The literature and our results suggest that epigenetic changes play important roles in 
breast cancer drug resistance. While the role of global DNA methylation in drug resistant 
breast cancer cells was shown, the exact nature of these epigenetic phenomena in cells 
resistant to cytotoxic DNA damaging agents and anti-estrogen agents need to be defined 
and compared. This is especially important, since it was recently proven that alterations 
in DNA methylation in cancer cells occur in defined regions, suggesting locus-specific 
and non-random global DNA dysregulation
98,105,106
.    
Furthermore, the phenomenon of drug resistance has not been fully explored in the 
microRNAome domain. The precise roles of differentially expressed miRNAs in 
cytotoxic and anti-estrogen drug resistance must be delineated and compared.  
Such an approach will allow us to resolve the epigenetically affected loci and identify 
differentially expressed miRNAs that may serve as general and/or drug-specific markers 
of chemoresistance. Additionally, this research will enable us to define the resistance 
changes that are specific to cytotoxic chemotherapy.   
The epigenome is a plastic characteristic of cells that responds acutely to stimuli within a 
cells environment.  Epigenetic changes allow for flexible control over gene expression, 
thus, impacting a multitude of cellular processes.  Unfortunately, besides maintaining a 
regulated homeostatic state, epigenetic modifications have been implicated in disease 
onset and progression including malignant transformation.  Furthermore, epigenetic 
mechanisms have a large impact on genomic stability.  Yet again, genomic instability is 
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known to play an integral role in disease.  Therefore, it is important to explore the role of 
epigenetics in acquired drug resistance of cancerous cells; cells known to display altered 
epigenetic patterns and genomic instability.  
I hypothesize that: 
1.  Drug resistant cells will exhibit a well-defined pattern of DNA methylation at a 
variety of loci. These changes may be linked to the expression of the given loci, thus 
contributing to the drug resistant phenotype.   
2.  MicroRNAome changes play a crucial etiological role in the generation and 
maintenance of drug resistance and that this dysregulation will be a common feature for 
resistance to DNA damage-inducing agents.  Alterations of these miRNAs by means of 
their over expression or targeted inhibition may lead to changes in the resistant 
phenotype.     
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Figure 1.1  Molecular mechanisms of drug resistance
1
. 
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 2.  Involvement of microRNA-451 in resistance of the MCF7 breast cancer cells to 
the chemotherapeutic drug doxorubicin 
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Pogribny IP.  Involvment of micrRNA-451 in resistance of the MCF7 breast cancer cells 
to the chemotherapeutic drug doxorubicin.  Mol Cancer Ther, 2008:7(7): 2152-2159. 
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2.1  Abstract 
Many chemotherapy regiments are successfully used to treat breast cancer; however, 
often breast cancer cells develop drug resistance that usually leads to a relapse and 
worsening of prognosis. We have shown recently that epigenetic changes such as DNA 
methylation and histone modifications play an important role in breast cancer cell 
resistance to chemotherapeutic agents. Another mechanism of gene expression control is 
mediated via the function of small regulatory RNA, particularly microRNA; its role in 
cancer cell drug resistance still remains unexplored. In the present study, we investigated 
the role of miRNA in the resistance of human MCF-7 breast adenocarcinoma cells to 
doxorubicin (DOX). Here, we for the first time show that DOX-resistant MCF-7 cells 
(MCF-7/DOX) exhibit a considerable dysregulation of the miRNAome profile and 
altered expression of miRNA processing enzymes Dicer and Argonaute 2. The 
mechanistic link of miRNAome deregulation and the multidrug resistant phenotype of 
MCF-7/DOX cells was illustrated by a remarkable correlation between specific miRNA 
expression and corresponding changes in protein levels of their targets, specifically those 
ones that have a documented role in cancer drug resistance. Furthermore, we show that 
microRNA-451 regulates the expression of multidrug resistance 1 gene. More 
importantly, transfection of the MCF-7/DOX-resistant cells with microRNA-451 resulted 
in the increased sensitivity of cells to DOX, indicating that correction of altered 
expression of miRNA may have significant implications for therapeutic strategies aiming 
to overcome cancer cell resistance. 
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2.2  Introduction 
Resistance of cancer cells to chemotherapy continues to be a major clinical obstacle to 
the successful treatment of cancer, including breast cancer
14,107,108
. Causes of cancer-
specific drug resistance are currently believed to be linked to the random drug-induced 
mutational events (genetic hypothesis), to the drug-induced non-mutational alterations of 
gene function (epigenetic hypothesis), and, recently, to the drug-induced karyotypic 
changes (karyotypic hypothesis
49,51,52,63,109
). The absence of convincing evidence that 
genetic changes have a role in acquired clinical resistance following anticancer therapy 
undermines the genetic hypothesis
63
. In contrast, conclusive data show that increased 
resistance of cancer cells to chemotherapeutic agents is associated with epigenetic 
alterations that include changes in DNA methylation and histone modifications
49,63,109
. 
The karyotypic hypothesis
52
 is closely related to the epigenetic one in view of the well 
known fact that epigenetic changes are a necessary prerequisite to karyotypic changes
110
. 
In this regard, karyotypic changes may be considered as a consequence of the epigenetic 
alterations progression and may serve as indirect evidence of the importance of 
epigenetic dysregulation in the acquisition of cancer drug resistance.  
 
Currently, extensive studies have indicated the existence and importance of another 
mechanism of nonmutational regulation of gene function mediated by means of short 
noncoding RNA
111-113
. Aberrant levels of microRNA (miRNA) have been reported in a 
variety of human cancers
65,114
, including breast cancer
115,116
. They have been shown to 
have both diagnostic and prognostic significance and to constitute a novel target for 
cancer treatment
117,118
. Considering the critical role of miRNA in cancer, we 
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hypothesized that the acquisition of drug resistance by cancer cells may also be 
modulated via the changes in miRNA levels. A recent study by Climent et al.
119
 suggests 
that the increased sensitivity of breast cancer patients to anthracycline-based 
chemotherapy may be related to the deletion of chromosome 11q, a region containing 
miR-125b gene. This finding was the first evidence to indicate a possible link between 
miRNA dysregulation and cancer drug resistance; however, the role of miRNA in the 
acquisition of drug resistance by cancer cells still remains elusive.   
 
Our present study for the first time shows that breast cancer cells resistant to doxorubicin 
(DOX) exhibit a pronounced deregulation of miRNA expression and the altered 
expression of miRNA processing enzymes. Moreover, we show that microRNA-451 
(miR-451) regulates the expression of the multidrug resistance 1 (mdr1) gene, a crucial 
factor in drug resistance, and this interaction may have an important functional 
consequence in the formation of cancer cell resistance to chemotherapeutic agents. 
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2.3  Materials and Methods 
2.3.1  Cell Lines and Cell Culture 
The human breast adenocarcinoma MCF-7 cell line and MCF-7/DOX were cultured 
using Iscove‘s modified Dulbecco medium (Sigma) containing 10% newborn calf serum 
(HyClone) and 40 μg/mL gentamicin at 37°C in a 5% CO2 atmosphere. The MCF-7/DOX 
drug-resistant variant of the MCF-7 cell line was established by stepwise selection after 
prolonged (>6 months) treatment of MCF-7 cells to increasing concentrations of DOX at 
a range of 0.5 to 25 μmol/L in the medium21. After 6 months of culturing in the presence 
of DOX, the IC50 (inhibitory concentration to produce 50% cell death) values were 24 
and 1 μmol/L DOX for the MCF-7/DOX and parental MCF-7 cells, respectively. Cells 
were seeded at a density of 0.5 X 10
6
 viable cells per 100 mm plate, and the medium was 
changed every other day for 6 days. Trypsinized cells were washed in PBS and 
immediately frozen at -80°C for subsequent analyses. The experiments were 
independently reproduced twice, and each cell line was tested in triplicate.   
 
2.3.2  Immunocytochemistry and Immunofluorescence 
Expression of P-glycoprotein (P-gp), a product of the mdr1 gene, in the MCF-7 and 
MCF-7/DOX cells was detected by immunocytochemistry as described by Chekhun et 
al.
21
 and by immunofluorescence. Cells were cultured on glass coverslips for 24 h and 
fixed in PBS containing 0.4% paraformaldehyde. The fixed cells were then rinsed with 
PBS and incubated with the primary mouse anti-human P-gp monoclonal (clone C494) 
antibodies (DAKO) diluted 1:100 at room temperature for 60 min. Horseradish 
peroxidase–coupled secondary antibodies and DAKO EnVision System were used for 
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visualization. For immunofluorescence, the fixed and permeabilized cells were incubated 
with the primary anti- P-gp antibodies (1:100; Abcam). After washing, the cells were 
incubated with Alexa Fluor secondary antibodies and counterstained with 4‘,6-diamidino-
2-phenylindole.   
 
2.3.3 miRNA Microarray Expression Analysis  
Total RNA was extracted from MCF-7 and MCF-7/DOX cells using TRIzol Reagent 
(Invitrogen) according to the manufacturer‘s instructions. The miRNA microarray 
analysis was done by LC Sciences. Total RNA (10 μg) was size fractionated (<200 
nucleotides) by using a mirVana kit (Ambion) and labelled with Cy3 and Cy5 fluorescent 
dyes. Dye switching was done to eliminate the dye bias. Pairs of labelled samples were 
hybridized to dual-channel microarrays. Microarray assays were done on a μParaFlo 
microfluidics chip with each of the detection probes containing a nucleotide sequence of 
coding segment complementary to a specific miRNA sequence and a long non-nucleotide 
molecule spacer that extended the detection probe away from the substrate. 
 
A miRNA detection signal threshold was defined as twice the maximum background 
signal. The maximum signal level of background probes was 180. Normalization was 
done using a cyclic LOWESS (locally weighted regression) method to remove the 
system-related variations
120
. Data adjustments included data filtering, log2 
transformation, and gene centering and normalization. The t test analysis was conducted 
between MCF-7 and MCF-7/DOX samples, and miRNA with p values < 0.05 were 
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selected for cluster analysis. The clustering analysis was done using a hierarchical 
method and average linkage and Euclidean distance metrics
121
. 
 
2.3.4  Quantitative Real-time PCR Analysis for miRNA Expression 
The quantitative real-time PCR (qRT-PCR) was done by using SuperTaq Polymerase 
(Ambion) and a mirVana qRT-PCR miRNA Detection Kit (Ambion) following the 
manufacturer‘s instructions. Reactions contained mirVana qRT-PCR Primer Sets 
(Ambion) specific for human miR-127, miR-200a, miR-200c, miR-34a, miR-15a, miR-
16, miR27b, let-7, miR-21, miR-28, miR-106a, miR-206, and miR-345. Human 5S rRNA 
served as a positive control. qRT-PCR was done on a SmartCycler (Cepheid). The level 
of each miRNA expression was measured using the 2
-ΔΔCt
 method 
122
. The results are 
presented as fold change of each miRNA in the MCF-7/DOX cells relative to the parental 
MCF-7 cells. 
 
2.3.5  Western Immunoblotting 
Total cellular extracts were prepared by homogenization of 3X10
6
 to 5X10
6
 cells in 500 
μL lysis buffer [50 mmol/L Tris-HCl (pH 7.4); 1% NP-40; 0.25% sodium deoxycholate; 
150 mmol/L NaCl; 1 mmol/L EDTA; 1 mmol/L phenylmethylsulfonyl fluoride; 1 μg/mL 
each of aprotinin, leupeptin, and pepstatin; 1 mmol/L Na3VO4; and 1 mmol/L NaF], 
sonication, and incubation at 4°C for 30 min followed by centrifugation at 10,000X g at 
4°C for 20 min. Small aliquots (10 μl) of extracts were reserved for protein determination 
using protein assay reagents from Bio-Rad. Equal amounts of proteins (20 μg) were 
separated by SDS-PAGE in slab gels of 8% or 12% polyacrylamide, made in duplicate, 
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and transferred to polyvinylidene difluoride membranes (GE Healthcare Biosciences). 
The membranes were incubated with antibodies against Dicer (1:500; Santa Cruz 
Biotechnology), AGO2 (1:500; Santa Cruz Biotechnology), RB1 (1:750; Labvision 
Neomarkers), PTEN (1:1000; Cell Signalling Technology), K-RAS (1:500; Santa Cruz 
Biotechnology), CYP1B1 (1:500; Santa Cruz Biotechnology), ERa (1:500; Cell 
Signalling Technology), P-gp (1:200; Abcam), BCL6 (1:200; Santa Cruz Biotechnology), 
BRCA1 (1:200; Santa Cruz Biotechnology), and NOTCH1 (1:250; Abgent). Antibody 
binding was revealed by incubation with horseradish peroxidase–conjugated secondary 
antibodies (Santa Cruz Biotechnology) and an ECL Plus immunoblotting detection 
system (GE Healthcare Biosciences). Chemiluminescence was detected by GE ECL 
Hyperfilm (GE Healthcare Biosciences). The unaltered polyvinylidene difluoride 
membranes were stained with Coomassie blue (Bio-Rad), and the intensity of the Mr 
50,000 protein band was assessed as a loading control. Signals were quantified using NIH 
ImageJ 1.63 Software.  
 
2.3.6  Luciferase Reporter Assay for Targeting the mdr1 3‘-Untranslated Region  
For the luciferase reporter experiments, a 3‘-untranslated region (UTR) segment of mdr1 
gene corresponding to a region of 610 bp (4,262-4,872 nucleotides of the total transcript) 
for mdr1 (accession no. NM_000927) was amplified by PCR from human genomic DNA 
using primers that included a XbaI and EcoRI tails on the 5‘ and 3‘ strands, respectively. 
PCR products were restricted with both XbaI and EcoRI restriction endonucleases and 
then gel purified. The amplified 3‘-UTR of mdr1 contains a XbaI restriction site; 
therefore, mdr1-3‘-UTR was ligated into the pGL3-control vectors (Promega) by using 
39 
 
the XbaI site located immediately downstream of the stop codon of luciferase. The 
HEK293 cells were transfected with the firefly luciferase UTR-report vector, control 
Renilla luciferase pRL-TK vector (Promega), and precursor miR-451 for the mdr1-3‘-
UTR construct using LipofectAMINE 2000 reagent according to the manufacturer‘s 
protocol (Invitrogen). Twenty-four hours after transfection, cells were lysed with a 1X 
passive lysis buffer and the activity of both Renilla and firefly luciferases was assayed 
using the dual-luciferase reporter assay system (Promega) according to the 
manufacturer‘s instructions.  
 
2.3.7  Cell Survival Analysis 
The MDR-7/DOX cells were seeded in six-well plates at density of 1X10
5
/mL and 
transfected with scrambled RNA oligonucleotide (control) or 100 nmol/L miR-451 
(Ambion) in three independent replicates LipofectAMINE 2000 reagent according to the 
manufacturer‘s protocol (Invitrogen). Seventy-two hours after transfection, cells were 
reseeded in 96-well plates in the presence of miR-451 at density of 1X10
4
 per well and 
treated with DOX at a range of concentration of 2.5 to 200 μmol/L in the medium for 72 
h.  Cell survival was analyzed by using the CellTiter-Blue Cell Viability Assay 
(Promega). 
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2.4  Results 
2.4.1  Expression of miRNA in MCF-7 and MCF/DOX Breast Cancer Cells 
miRNA microarrays were used to analyze the miRNA expression profiles in the human 
breast adenocarcinoma MCF-7 cell line and its drug-resistant MCF-7/DOX variant. The 
cluster analysis revealed that the MCF-7 breast cancer cells with acquired resistance to 
DOX were characterized by significant changes in miRNA expression. We identified 137 
miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed 
(P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells. 
Furthermore, 84 of these miRNA genes were differentially expressed at a level of P < 
0.01 (Fig. 2.1A). The results obtained by miRNA microarray analysis were independently 
confirmed by the qRT-PCR. We analyzed the status of differentially expressed miR-127, 
miR-200a, miR-200c, miR-34a, miR-15a, miR-16, miR27b, let-7, miR-21, miR-28, miR-
106a, miR-206, and miR-345 genes in MCF-7 and MCF-7/DOX cells. The qRT-PCR 
confirmed the data obtained by microarray analysis (Fig. 2.1).   
 
2.4.2 Expression of Dicer and Argonaute 2 Proteins in MCF-7 and MCF/DOX Breast 
Cancer Cells 
Having revealed the profound alterations in the miRNA profile in the MCF-7/DOX drug-
resistant cells, we decided to analyze the protein levels of the main miRNA processing 
enzyme, Dicer. Several studies pointed toward the putative role of Dicer in 
tumorigenesis
116,123,124
; however, its involvement in cancer drug resistance has not been 
addressed yet. Figure 2.1C shows a very strong down-regulation of Dicer levels in the 
MCF-7/DOX cells.  Additionally, we have detected a pronounced down-regulation of the 
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Argonaute 2 protein, a member of Argonaute protein family that has an important role in 
RNA silencing
125
 in theMCF-7/DOX cells compared with MCF-7 cells. The significantly 
decreased levels of the Dicer and Argonaute 2 proteins may, in part, explain the 
profoundly dysregulated miRNAome profile in the MCF-7/DOX cells. 
 
2.4.3  Association between miRNA Expression and Levels of miRNA Target Proteins 
To establish the significance of miRNA expression dysregulation with respect to the 
acquired cancer cell drug resistance, we determined the protein levels of the 
experimentally confirmed targets of these differentially expressed miRNA. We found a 
strong negative correlation between expression of particular miRNA and levels of 
confirmed target proteins associated with cancer cell drug resistant phenotype. For 
instance, Western blot analysis of the MCF-7/DOX cells showed the increased levels of 
anti-apoptotic proteins BCL6, NOTCH1, and K-RAS and up-regulation of CYP1B1 
protein leading to the increased metabolism of DOX. The up-regulation of these proteins 
was associated with down-regulation of the corresponding miRNA: miR-127, miR-34a, 
miR-27b, and let-7
126-130
, respectively (Fig. 2.1D). In contrast, up-regulation of the miR-
206, miR-106a, miR-21, and miR-214 miRNA (Fig. 2.1A and B; Supplementary Table 
S1) in MCF-7/DOX cells was associated with the decreased level of their targets ERa, 
RB1, and PTEN proteins
131-135
, respectively, resulting in estrogen insensitivity and 
increased survival of MCF-7/DOX resistant cells. Additionally, MCF-7/DOX cells were 
characterized by aberrant expression of several miRNA, such as miR-10, miR-21, miR-
155, and miR-200c, associated with increased cell invasion and metastasis
135-137
. 
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2.4.4  miR-451Regulates Expression of mdr1 
One of the major mechanisms involved in cancer cell resistance to chemotherapeutic 
agents is an increased energy-dependent efflux of drugs from cancer cells mediated by 
the ATP-binding cassette transporter P-gp, which is encoded by the mdr1 gene
14,15
. 
Several studies have shown a critical role of this protein in the intrinsic or acquired drug 
resistance
14,138
. The importance of epigenetic mechanisms in the regulation of the mdr1 
gene has also been well documented
21,139,140
. Specifically, the increased resistance of 
cancer cells, including breast cancer cells, to chemotherapy is associated with 
pronounced hypomethylation and altered histone modifications at the mdr1 promoter 
region and up-regulation of the mdr1 gene expression
21,139,140
; however, the role of 
miRNA in the mdr1 regulation has not been addressed. Figure 2.2 shows that the MCF-
7/DOX cells exhibit very high levels of P-gp, a product of mdr1 gene, compared with the 
parental MCF-7 cells as detected by immunocytochemistry and immunofluorescence.  
 
Computational analysis of the 3‘-UTR of mdr1 revealed a putative binding site for a 
single miRNA, miR-451, mature sequence UUGAGUCAUUACCAUUGCCAAA, at 
4,742 to 4,763 nucleotides (Fig. 2.3A). This prediction was further confirmed by the 
miRGen software
141
. Therefore, we determined the role of miR-451 in the regulation of 
mdr1expression. The cellular level of this miRNA in the MCF-7/DOX cells was below 
the detection limit of the microarray. To examine whether mdr1 is indeed functionally 
targeted by miR-451, the segment of mdr1-3‘-UTR containing the miR-451 
complementary site was cloned into the 3‘-UTR of a luciferase reporter system. The 
resulting reporter vector was transfected into the HEK293 cells together with transfection 
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controls and miR-451, anti-miR-451, or miRNA that do not have binding sites within the 
3‘-UTR of mdr1.  
 
Figure 2.3B shows that miR-451 inhibited the luciferase activity from the construct with 
the mdr1-3‘-UTR segment in a concentration-dependent manner (Fig. 2.3B). There was 
no change in the luciferase reporter activity when the cells were cotransfected with the 
negative control (scrambled oligonucleotides) or unrelated miRNA such as miR-7, miR-
127, or miR-345 (data not shown). No luciferase expression changes were observed when 
the cells were transfected with the plasmid lacking the mdr1-3‘-UTR fragment (data not 
shown). 
 
To further confirm that miR-451 indeed affects the protein levels of P-gp in the 
MCF7/DOX cells, these cells were transfected with either the miR-451 or miR-451 and 
anti-miR-451, and the level of P-gp was determined by Western blotting 48 h after 
transfection. Figure 2.3C shows that transfection of MCF-7/DOX cells with miR-451 
resulted in a decrease of P-gp levels, whereas the simultaneous transfection of miR-451 
and anti-miR-451abolished the inhibitory effect of miR-451 efficiently.  
 
2.4.5  Inhibition of mdr1 Expression Results in the Increased Sensitivity of theMCF-
7/DOX Cells to DOX  
The finding that the miR-451 targets mdr1 suggested that down-regulation of expression 
of this miRNA contributes to the cancer drug resistance; therefore, the restoration of a 
miR-451 level in the resistant MCF-7/DOX cells may increase their sensitivity to DOX. 
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To address this issue, we transfected MCF-7/DOX with miR-451 and determined the 
sensitivity of cells to DOX treatment. Figure 3.3D shows that transfection of MCF-
7/DOX cells with miR-451 resulted in the increased sensitivity of the resistant MCF-
7/DOX cells to DOX. The IC50 of MCF-7/DOX cells transfected with miR-451 was 2.5 
times lower (P < 0.05) compared with the MCF-7/DOX cells transfected with scrambled 
oligonucleotide. In contrast, transfection of MCF-7 cells resistant to cis-
dichlorodiammine platinum with miR-451 did not change sensitivity of the MCF-7/cis-
dichlorodiammine platinum–resistant cells to cis-dichlorodiammine platinum treatment 
(data not shown). 
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2.5  Discussion 
Recent findings have confirmed a critical role of miRNA as powerful diagnostic and 
prognostic indicators of human breast cancer
115,116,136,137,142
, resulting in the development 
of novel approaches to breast cancer management
142
. Despite the well-established role of 
miRNA in cancer
65,115
 and the dedication of research and resources to the elucidation of 
the molecular mechanisms involved in the development of resistant cancer cells to 
chemotherapy, the role of miRNA in cancer drug resistance remains largely unexplored. 
In this report, we provide data indicating the importance of miRNA dysregulation in the 
acquisition of cancer cell resistance to chemotherapeutic drugs. This was evidenced by 
the pronounced alteration in expression of miRNA genes in the MCF-7/DOX-resistant 
cells compared with parental MCF-7 cells. The mechanistic connection of miRNAome 
dysregulation with the establishment of a multidrug-resistant phenotype in MCF-7/DOX 
cells was evidenced by the correlation between expression of specific miRNA and 
corresponding changes in the protein levels of their targets, specifically those targets that 
have a documented importance in the development of cancer cell drug resistance. At 
present, the cancer drug resistance is considered as a multifactorial phenomenon 
involving several major mechanisms, such as decreased uptake of water-soluble drugs, 
increased repair of DNA damage, reduced apoptosis, altered metabolism of drugs, and 
increased energy-dependent efflux of chemotherapeutic drugs that diminish the ability of 
cytotoxic agents to kill cancer cell
107,109
. The pattern of miRNA expression in the MCF-
7/DOX cells affecting multiple genes simultaneously provided support for this 
multifactorial polygenic drug resistance hypothesis. This was evidenced by (a) down 
regulation of miR-27b and consequent up-regulation of CYP1B1 leading to the increased 
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metabolism of DOX; (b)down-regulation of miR-127 and miR-34a resulting in a reduced 
apoptotic program via inhibition of p53 network; (c) down-regulation of miR-200c 
resulting in up-regulation of TCF8
137
 and consequent decreased expression of E-cadherin 
inducing cell invasiveness and metastasis, (d)up-regulation of miR-21 and miR-214 
targeting PTEN
133,134
 leading to increased cell survival; (e) up-regulation of miR-28 
leading to loss of BRCA1 expression, which is associated with increased resistance to 
DOX treatment
143
; and (f) up-regulation of miR-206 leading to loss of the ERa-mediated 
signal transduction. Furthermore, our results of miR-125 down regulation in the MCF-
7DOX-resistant cells support suggestion by Climent et al. 
119
 regarding the link between 
miRNA dysregulation and breast cancer drug resistance. 
 
Because the increased energy-dependent efflux of chemotherapeutic drugs is a major 
mechanism associated with resistance of cancer cells to DOX, we have focused on a 
potential role of miRNA as regulators of the mdr1expression. Our reporter assay 
experiments show significant reduction of MDR1 expression, clearly indicating that miR-
451 is a regulator of MDR1. More importantly, transfection of the MCF-7/DOX cells 
with miR-451 resulted in the increased sensitivity of resistant cells to DOX. This finding 
indicates that correction of altered expression of miRNA may have significant 
implications for therapeutic strategies aiming to overcome cancer cell resistance. Indeed, 
recent reports on the positive results in the use of small interfering RNA 
144,145
 or miRNA 
146
 to suppress resistance of cancer cells to chemotherapeutic drugs support this 
suggestion.  In our previous study using MCF-7/DOX cells, we have found profound 
alterations of cellular epigenetic landscape
21
 (20), including hypomethylation of the mdr1 
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gene. Those epigenetic abnormalities in MCF-7/DOX cells, specifically loss of cytosine 
methylation, may be partially related to the increased expression of miR-22, miR-29a, 
miR-194, and miR-132 miRNA that target DNA methyltransferases 3A and 3B and 
methyl CpG binding protein 2
147,148
. 
In conclusion, we have shown that the development of multidrug resistance is associated 
with the pronounced deregulation of miRNA expression. Additionally, we have shown 
that expression of miR-451 is inversely correlated with mdr1 expression in breast cancer 
drug-resistant cells. Furthermore, the enforced increase of miR-451 levels in the MCF-
7/DOX cells down-regulates expression of mdr1 and increases sensitivity of the MCF-7-
resistant cancer cells to DOX. These results provide a strong rationale for the 
development of miRNA-based therapeutic strategies aiming to overcome cancer cell 
resistance. However, these alterations are not necessarily indicative of the causative role 
of miRNA deregulation in the cancer drug resistance development and the ultimate goal 
of future studies is to address this question. 
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Figure 2.1.  MicroRNAome changes in the drug resistant breast cancer cells.   
A) Expression of miRNAs in MCF7 and MCF7/DOX breast cancer cells. B) qRT-PCR 
confirmation of miRNA microarray analysis, data presented as fold change compared to 
control (p<0.05). C) Levels of dicer and Ago2 protiens in mCF7 and MCF7/DOX cells. 
D) Changes in the expression of selected confirmed miRNA targets. 
A
Differentially expressed miRNAs in MCF-7/DOX cells
MicroRNA Fold change Protein targets
Down-regulated
hsa-miR-127 -17.4 BCL6
hsa-miR-200c -32.1 TCF8 (ZEB1)
hsa-miR-34 -7.1 E2F3, Notch1
hsa-miR-27b -2.2 CYP1B1, Notch1
hsa-miR-21 -4.4 PTEN
hsa-let-7 -1.3 K-RAS
Up-regulated
hsa-miR-28 4.6 none
hsa-miR-22 6.5 none
hsa-miR-106 2.0 RB1
hsa-miR-206 4.8 ERα
B
C
D
DICER1
AGO2
MCF-7 MCF-7/DOX
MCF-7 MCF-7/DOX
-2.2                       0.0                       2.2
NOTCH1
K-RAS
PTEN
E2F1
RB1
CYP1B1
MCF-7 MCF-7/DOX
ERα
p73
β-actin
BCL-6
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Figure 2.2 . The resistant cells display different levels of expression of P-gp. 
Expression in the MCF7 and MCF7/DOX human breast adenocarcinoma cells as detected 
by immunocytochemistry (A and C), immunofluorescence (B and D) and 
immunoblotting (E). 
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Figure 2.3. miR-451 regulates expression of mdr1. 
(A) A putative miR-451 binding site at the 3‘UTR of mdr1, as identified using MiRanda 
software. (B) miR-451 inhibits luciferase activity in a concentration-dependent manner 
from the construct with the mdr1-3‘UTR segment. (C) Transfection of MCF-7/DOX cells 
with mir-451 results in a decrease of Pgp (MDR1 product) levels, while the simultaneous 
transfection of miR-451 and anti-miR-451 efficiently abolishes the inhibitory effect of 
miR-451. (D) Suppression of MDR1 expression by miR-451 results in increase 
sensitivity of MCF-7/DOX cells to DOX. 
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3.  Alterations of microRNAs and their targets are associated with acquired 
resistance of MCF-7 breast cancer cells to cisplatin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 accepted for publication in its entirety: 
Pogribny, IP., Filkowski, JN., Tryndyak VP., Golubov, A., Shpyleva, SI., and Kovalchuk 
O.  Alterations of microRNAs and their targets are associated with acquired resistance 
MCF7 breast cancer cells to cisplatin.  Int. J. Cancer 2010, 127: 1785-1794. 
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3.1  Abstract 
Cancer cells that develop resistance to chemotherapeutic agents are a major clinical 
obstacle in the successful treatment of breast cancer. Acquired cancer chemoresistance is 
a multifactorial phenomenon, involving various mechanisms and processes. Recent 
studies suggest that chemoresistance may be linked to drug-induced dysregulation of 
microRNA function. Furthermore, mounting evidence indicates the existence of 
similarities between drug-resistant and metastatic cancer cells in terms of resistance to 
apoptosis and enhanced invasiveness. We studied the role of miRNA alterations in the 
acquisition of cisplatin-resistant phenotype in MCF-7 human breast adenocarcinoma 
cells. We identified a total of 103 miRNAs that were over expressed or under expressed 
(46 up regulated and 57 down regulated) in MCF-7 cells resistant to cisplatin. These 
differentially expressed miRNAs are involved in the control of cell signalling, cell 
survival, DNA methylation and invasiveness. The most significantly dysregulated 
miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c. 
Furthermore, we demonstrated that miR-345 and miR-7 target the human multidrug 
resistance-associated protein 1. These results suggest that dysregulated miRNA 
expression may underlie the abnormal functioning of critical cellular processes associated 
with the cisplatin-resistant phenotype. 
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3.2  Introduction 
Breast cancer is the most common malignancy in women. In the United States, the 
incidence of invasive breast cancer, the most serious form of breast cancer, was estimated 
as 182,460 new cases and 40,480 deaths in 2008
2
. Despite advances in understanding the 
molecular mechanisms of breast cancer biology, as well as advances in early detection 
and treatment, in 50% of cases cancer cells will either rapidly acquire resistance against 
numerous cytotoxic drugs or are intrinsically resistant
149
. Furthermore, ~30% of all 
patients with early-stage breast cancer will have recurrent disease, which becomes 
predominantly metastatic and resistant to treatment
6,150
. It is believed that resistance to 
chemotherapy or administration of ineffective chemotherapeutic agents causes treatment 
failure in 90% of patients with metastatic cancer
6
. Currently, acquired drug resistance and 
metastasis are major obstacles in the successful treatment of breast cancer
151,152
. Thus, 
increasing tumour cell sensitivity to chemotherapeutic agents and predicting 
chemotherapeutic agent effectiveness without developing drug resistance in individual 
patients are attractive goals for improving the clinical management of cancer. Recent 
evidence suggests that drug-induced dysregulation of microRNA (miRNA) function may 
modulate the sensitivity of cancer cells to chemotherapeutic agents and may be involved 
in the acquisition of cancer cell resistance to chemotherapy
49,70
, including breast cancer 
drug resistance
153-155
, and breast cancer metastasis
136,156
. In addition, there is increasing 
evidence that there are great similarities between drug-resistant and metastatic cancer 
cells; particularly, in terms of profound resistance to apoptosis and enhanced 
invasiveness
157
. With this in mind, the aims of this study were as follows: (i) to determine 
whether or not the acquired drug-resistant phenotype of breast cancer cells to cisplatin 
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(cis- dichlorodiammine platinum (II) (CDDP)), a major chemotherapeutic agent used to 
treat a range of human malignancies
158
, is associated with secondary miRNA alterations 
and (ii) to determine whether or not these miRNA abnormalities are associated with 
specific known mechanisms of cisplatin based resistance.  
 
55 
 
3.3  Materials and Methods 
3.3.1  Cell lines and cell culture 
The MCF-7 and MDA-MB-231 human breast cancer lines were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA) and were maintained 
according to ATCC‘s recommendations. Cisplatin (CDDP) is a chemotherapeutic agent 
used to treat a range of cancers including ovarian and breast cancer
159,160
. The MCF-7 
drug-resistant variant to CDDP (MCF-7/CDDP) cell line was established by stepwise 
selection after prolonged (>6 months) treatment of MCF-7 cells to increasing 
concentrations of CDDP (Sigma) at a range of 0.5–25 μM in the medium21. After 6 
months of culturing in the presence of CDDP, the IC50 (inhibitory concentration to 
produce 50% cell death) values were 94 and 12 μM of CDDP for the MCF-7/CDDP and 
parental MCF-7 cells, respectively. Cells were seeded at a density of 0.5 X10
6
 viable 
cells per 100 mm plate, and the medium was changed every other day for 6 days. 
Trypsinized cells were washed in phosphate-buffered saline and immediately frozen at -
80°C for subsequent analyses. The experiments were independently reproduced twice, 
and each cell line was tested in triplicate.  
 
3.3.2  miRNA microarray expression analysis 
Total RNA was extracted from MCF-7 and MCF-7/CDDP cells using TRIzol reagent 
(Invitrogen, Burlington, ON) according to the manufacturer‘s instructions. The miRNA 
microarray analysis was performed by LC Sciences (Houston, TX). Ten micrograms of 
total RNA was size-fractionated (<200 nucleotides) by using a mirVana kit (Ambion, 
Austin, TX) and labelled with Cy3 and Cy5 fluorescent dyes. Dye switching was 
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performed to eliminate dye bias. Pairs of labelled samples were hybridized to dual-
channel microarrays. 
 
Microarray assays were performed on a lParaFlo microfluidics chip with each of the 
detection probes containing a nucleotide sequence of coding segment complementary to a 
specific miRNA sequence and a long non-nucleotide molecule spacer that extended the 
detection probe away from the substrate. A miRNA detection signal threshold was 
defined as twice the maximum background signal. The maximum signal level of 
background probes was 180. Normalization was performed using a cyclic LOWESS 
(locally weighted regression) method to remove system-related variations
120,154
. Data 
adjustments included data filtering, log2 transformation, gene centering and 
normalization. T-test analysis was conducted between MCF-7 and MCF-7/CDDP 
samples, and miRNAs with p-values < 0.05 were selected for cluster analysis. The 
clustering analysis was performed using a hierarchical method and average linkage and 
Euclidean distance metrics
121,154
.  
 
3.3.3  Quantitative real-time PCR analysis for miRNA expression  
The qRT-PCRs were performed by using SuperTaq Polymerase (Ambion, Austin, TX) 
and a mirVana qRT-PCR miRNA Detection Kit (Ambion) following the manufacturer‘s 
instructions.  Reactions contained mirVana qRT-PCR primer sets (Ambion) specific for 
human miR-127, miR-126, miR-200c, miR-29a, miR-29b, miR-206 and miR-345. 
Human 5S rRNA served as an internal control. qRT-PCR was performed on a 
SmartCycler (Cepheid, Sunnyvale, CA), and each cell line was run in triplicate. The level 
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of each miRNA expression was measured using the 2
ΔΔCt
 method
122,154
. The results are 
presented as fold change of each miRNA in the MCF-7/CDDP cells relative to the 
parental MCF-7 cells. Indicated changes are significant at 95% confidence level (p 
<0.05).  
 
3.3.4  Western blot analysis of protein expression 
The protein levels of DNA methyltransferase 3A (DNMT3A), methyl-CpG-binding 
protein 2 (MeCP2), ZEB1, E-cadherin, MRP1 and b-actin in the MCF-7, MCF-7/CDDP 
cells were determined by Western blotting using protocols described previously
21,154,161
.  
 
3.3.5  Immunofluorescence  
Expression of ZEB1 and E-cadherin in the MCF-7 and MCF-7/CDDP cells was detected 
by immunofluorescence. Cells were cultured on glass coverslips for 24 hr and fixed in 
PBS containing 0.4% paraformaldehyde. Fixed and permeabilized cells were incubated 
with the primary ZEB1 (1:50, Santa Cruz Biotechnology) and E-cadherin (1:50, Cell 
Signalling).  After washing, the cells were incubated with Alexa Fluor secondary 
antibodies and counterstained with 40,6-diamidino-2-phenylindole (DAPI). 
 
3.3.6  Cytosine DNA methylation analysis 
The extent of global DNA methylation was evaluated with a cytosine extension assay as 
described previously
21,162
.  
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3.3.7  Analysis of the invasiveness of cisplatin-resistant MCF-7 cells  
MCF-7 and MCF-7/CDDP cells were plated in the upper chamber of BD BioCoat 
Matrigel Invasion Chambers (BD Biosciences, Bedford, MA) and grown as 
recommended by the manufacturer. After 48 hr, cells on the bottom side of membrane 
were stained and mounted onto glass slides, and the mean number of cells in 4 replicates 
was determined. Representative images (magnification 125X) of stained membranes are 
shown. 
 
3.3.8  Luciferase reporter assay for targeting MRP1-3‘-UTR 
Cloning of the UTR was based on transcript NM_004996 for the MRP1(Abcc1) gene. 
UTR was defined as the sequence between 4772 and 6564 bps. For the luciferase reporter 
experiments, a 30-UTR segment of the MRP1 gene (nucleotides 4742–6564) that 
contains putative binding regions for hsa-miR-345 (nucleotides 4819–4838, 
NM_004996) and hsamiR-7 (nucleotides 5346–5368) was amplified by PCR from human 
genomic DNA using primers that included an XbaI and EcoRI tails on the 50 and 30 
strand, respectively. PCR products were restricted with both XbaI and EcoRI restriction 
endonucleases and then gel purified. The amplified 3‘-UTR of MRP1 contains an XbaI 
restriction site; therefore, MRP1-3‘-UTR was ligated into the pGL3-control vectors 
(Promega, Madison, WI) by using the XbaI site located immediately downstream of the 
luciferase stop codon. In parallel, we mutated the miR-7 (nucleotides 5361–5368) and 
miR-345 (4830–4837) seed sequence-binding regions in the 3‘-UTR segment of the 
MRP1 gene to 50-AGAGGAAG-30 and 50-AAGAGAGA-30, respectively. HEK293 
cells were transfected with firefly luciferase MRP1-3‘-UTR construct or mutated MRP1-
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3‘-UTR construct, a control Renilla luciferase pRL-TK vector (Promega) and synthetic 
precursors of miR-345 and miR-7 (Ambion) using lipofectamine 2000 reagent according 
to the manufacturer‘s protocol (Invitrogen, Carlsbad, CA). Scrambled oligonucleotides or 
unrelated miRNA that is not predicted to target MRP1 (miR-127) (Ambion) served as 
controls. Twenty-four hours after transfection, cells were lysed with a 1X passive lysis 
buffer, and the activity of both Renilla and firefly luciferases was assayed using the dual-
luciferase reporter assay system (Promega) according to the manufacturer‘s 
instructions
154
. 
 
3.3.9  Analysis of the effect of miR-7 and miR-345 on cellular levels of MRP1  
MCF-7/CDDP cells were transfected with miR-7, miR-345 or scrambled RNA 
oligonucleotides (100 nM). Twenty-four hours after transfection, the cellular levels of 
MRP1 were detected by Western immunoblotting using anti-MRP1 antibodies (Abcam) 
according to the manufacturer‘s instructions.  
 
3.3.7  Statistical analysis 
Statistical analysis was performed using MS Excel 2007 and JMP5 software packages.  
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3.4 Results and Discussion 
Microarrays were used to analyze the expression of miRNAs in the MCF-7 human breast 
adenocarcinoma cell line and its cisplatin-resistant variant MCF-7/CDDP. Cluster 
analysis revealed that the MCF-7/CDDP cells were characterized by significant changes 
in miRNA expression. We identified 103 miRNA genes (46 up regulated and 57 down 
regulated) that were differentially expressed (p < 0.01) in the MCF-7/CDDP cells 
compared to the parental MCF-7 cells (Fig. 3.1). Microarray data were confirmed by 
qRT-PCR. Table 1 lists a number of miRNAs that exhibited pronounced changes in 
expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast 
cancer cells. Specifically, the MCF-7/CDDP cells were characterized by the greatest 
alterations in miRNAs involved in the control of several indispensable cellular processes 
and pathways, including cell signalling, cell survival and apoptosis, invasiveness and 
DNA methylation (Table 1). 
 
The most up regulated miRNAs in the MCF-7/CCDP cells were miR-146a, miR-10a and 
miR-221/222 (Table 3.1). These miRNAs regulate the cellular levels of breast cancer-
associated BCRA1 protein, homeobox family HOXD10, tumour suppressor p27 and 
estrogen receptor A
136,155,163-166
. The role of these proteins in the pathogenesis of breast 
cancer, cancer drug resistance and metastasis is well established
136,155,163-166
. Additionally, 
several miRNAs (miR-29a, miR-29b, miR-132 and miR-194), up regulated in MCF-
7/CDDP cells, are known to target DNA methyltransferases (DNMTs) and MeCP2 and 
therefore affect DNA methylation patterns
147,148
. Specifically, we found a significant up 
regulation of miR-29a and miR-29b (14.6 and 52.4 times, respectively), which target de 
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novo DNMT3A and -3B
147
. DNMT3A and -3B are de novo methyltransferases 
responsible for setting up DNA methylation patterns in the cells. Recently, Fabbri et al. 
have shown that the cellular levels of miR-29a and miR-29b are inversely correlated to 
DNMT3A and -3B in cancer tissues, and that miR-29a and miR-29b directly target both 
DNMT3A and -3B. Over expression of these miRNAs led to significant decreases in the 
DNMT3A and -3B levels
147
. In addition, MCF-7/CDDP cells were characterized by a 
significant (56.9 times) increase in the levels of miR-132 that targets MeCP2
148
. MeCP2 
is a transcriptional repressor that belongs to a family of methyl-CpG-binding domain 
proteins (MBD). MeCP2 selectively recognizes methylated DNA and plays a central role 
in chromatin remodelling. Recently, Klein et al. reported that MeCP2 translation is 
directly regulated by miR-132. Furthermore, blocking miR132-mediated repression 
effectively increased cellular MeCP2 levels
148
. 
  
In light of this, we analyzed whether or not the up regulation of miR-29a, miR-29b and 
miR-132 in the drug-resistant MCF-7/CDDP cells resulted in altered cellular levels of 
DNMT3A and MeCP2. As predicted, we found a significant decrease in the cellular 
levels of DNMT3A and MeCP2 in the MCF-7/CDDP drug-resistant cells (Fig. 3.2a). As 
dysregulation of DNA methyltransferases and methyl binding proteins is often associated 
with altered levels of DNA methylation, we next studied the status of global DNA 
methylation in parental MCF-7 cells and its MCF-7/CDDP drug-resistant variant. A well-
established cytosine extension assay confirmed that decreased cellular levels of 
DNMT3A and MeCP2 were accompanied by a significant decrease in global DNA 
methylation in the MCF-7/CDDP cells (Fig. 3.2b). It has been suggested that one of the 
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features of cancer drug-resistant cells is enhanced invasiveness
157
. Indeed, we detected 
altered expressions of several miRNAs, including miR-10a, miR-10b, miR126, members 
of miR-200 family (miR-200b, miR-200c, miR-141 and miR-429) and miR-205, whose 
aberrant expression has been linked to increased metastatic properties of breast cancer 
cells
136,156,167
.  Amongst these miRNAs, the most pronounced changes were specific for 
miR-200c and miR-200b, whose levels in MCF-7/CDDP cells were 497 and 1,000 times 
lower, respectively, when compared with parental MCF-7 cells (Table 1). These miRNAs 
play a major role in defining cellular epithelial phenotype by suppressing the expression 
of ZEB1/deltaEF1 and SIP1/ZEB2
167
. Both ZEB1 and SIP1 are transcriptional repressors 
of E-cadherin and have been implicated in the epithelial to mesenchymal transition 
(EMT). Manipulation of the miR-200 family can induce EMT
168
. EMT has been 
implicated in tumour progression and metastasis, and a major step in this process is the 
down regulation of E-cadherin
169,170
. A recent study by Gregory et al. provided evidence 
that ZEB1 and SIP1 expression is controlled by the miR-200 family and that   of miR-200 
is an essential early step in tumour metastasis
167
. In the MCF-7/CDDP cells, the 
decreased levels of the miR-200 family (Table 1) were associated with increased levels of 
ZEB1 protein and consequently with the decreased expression of E-cadherin (Fig.3.3a). 
Although ZEB1 is a nuclear protein, we noticed that immunofluorescence for ZEB1 still 
indicated some weak cytoplasmic staining for MCF-7 cells. In contrast, MCF-7/CDDP 
cells exhibited strong nuclear staining and some relatively strong cytoplasmic staining. 
Some weak cytoplasmic staining is sometimes observed in certain tumour cells
171-173
. 
This may be indicative of some basal levels of translation. Indeed, some basal low levels 
of ZEB1are also seen on the ZEB1 Western blot (Fig. 3.3b). Furthermore, the MCF-
63 
 
7/CDDP cells exhibited increased invasiveness when compared with the MCF-7 cells 
(Fig. 3.3b). Interestingly, the extent of the invasiveness of the MCF-7/CDDP cells was 
similar to the highly invasive MDA-MB-231 breast cancer cells (data not shown). More 
importantly, the IC50 (inhibitory concentration to produce 50% cell death) values for the 
MDA-MB-231 cells to CDDP (100 μM) were similar to that observed in the MCF-
7/CDDP cells. Regulation of drug efflux is yet another key mechanism involved in drug 
resistance
174
. Specifically, one of the mechanisms of resistance to platinum-based 
chemotherapeutic drugs in cancer cells is the formation of platinum and glutathione 
intracellular complexes
7,16,175
; however, these complexes are themselves toxic. It has been 
suggested that MRP1and MRP2 may mediate the resistance of cancer cells to cisplatin 
via enhancing the transport of cisplatin-glutathione-S conjugate out of cancer cells
7,16
. 
Indeed, the results of Negoro et al. recent study demonstrated the important role of MRP1 
and MRP2 up regulation in the establishment of a cisplatin-resistant cell line
17
. Using 
Western immunoblotting, we determined that cisplatin-resistant MCF-7/CDDP cells were 
characterized by a significant up regulation of MRP1 when compared with the sensitive 
MCF-7 cells (Fig. 3.4). Therefore, as a next step, we analyzed the profile of miRNA 
expression in MCF-7 and MCF-7/CDDP lines to identify any novel miRNAs that may 
potentially target efflux pumps. The results of miRNA microarray and qRT-PCR analyses 
demonstrate that one of the miRNAs with the greatest difference in MCF-7/CDDP 
expression was miR-345, whose expression was 17.0 times lower when compared with 
parental MCF-7 cells. While examining potential targets of miR-345 using several in 
silico methods for target gene predictions, such as Sanger miRNA database
176
 and 
miRGen miRNA database
141
, we noted that this miRNA may target the 30-UTR of the 
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human MRP1 (Abcc1) gene. Interestingly, the MRP1 gene was also predicted to be 
targeted by miR-7. MiR-7 levels are 2.3 times down regulated in MCF-7/CDDP cells 
when compared with MCF-7 cells. Detailed in silico analysis revealed that the 3‘-UTR of 
MRP1 contains putative regions (nucleotides 4819–4838, NM_004996 and nucleotides 
5346–5368, NM_004996) that match the sequences of hsa-miR-345 and hsa-miR-7, 
respectively (Fig. 3.5a). 
To validate these predicted miRNA-target interactions, the segment of MRP1-3‘-UTR 
(nucleotides 4742–6564) containing the miR-345 and miR-7 complementary sites was 
cloned into the 3‘-UTR of a luciferase reporter system. Additionally, we have mutated 
the miR-7 and miR-345 seed-interacting sequences in the MRP1-3‘-UTR. The resulting 
reporter vectors were transfected into HEK293 cells together with miRNA that do not 
have binding sites within the 3‘-UTR of the MRP1-luciferase UTR-report vector and 
either with miR-345 or miR-7 alone or with both miR-345 and miR-7. No change in the 
luciferase reporter activity was observed in HEK293 cells that were cotransfected with 
negative control (scrambled oligonucleotides) or unrelated miRNAs such as miR-127. In 
contrast, transfection of the HEK293 cells with either miR-345 or miR-7, or both 
miRNAs together, significantly inhibited luciferase activity from the construct with the 
MRP1-30-UTR segment. No luciferase inhibition was noted in the constructs containing 
mutated MRP1-3‘-UTR segments (Fig. 3.5b). Most importantly, transfection of the MCF-
7/CDDP cells with miR-345 and miR-7 resulted in a significant decrease in the cellular 
levels of MRP1 24 hr after transfection (Fig. 3.5c) and an increased sensitivity of MCF-
7/CDDP to CDDP, as evidenced by a decrease in IC50 values from 94 μM in MCF-
7/CDDP cells to 43 μM in MCF-7/CDDP cells transfected with miR-345 and miR-7 (Fig. 
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3.5d). Furthermore, one of the predicted targets of miR-489, down regulated in MCF-
7/CDDP cells, is MRP2 (Table 1). Thus, we concluded that miRNAs may be important 
regulators of the cellular levels of efflux pump proteins such as MRP1 and MRP2. 
Furthermore, this data further substantiate the previously reported role of miR-451 in the 
regulation of another efflux pump—MDR1, in another cancer drug-resistant cell line 
model—breast adenocarcinoma cells resistant to doxorubicin154. Overall, acquired drug 
resistance is a multifactorial phenomenon, involving multiple mechanisms and processes 
that include decreased uptake of drugs, alterations in cell cycle and signal transduction 
pathways, increased repair of DNA damage, reduced apoptosis, increased efflux of 
hydrophobic drugs, DNA damage tolerance and altered DNA methylation and chromatin 
structure. The results of our study demonstrate that dysregulation of miRNA expression 
is associated with abnormal functioning of some of the critical cellular processes 
associated with the drug-resistant phenotype in MCF-7/CDDP cells. Specifically, we 
identified miRNA changes associated with increased efflux of drugs, changed DNA 
methylation and altered DNA repair. We also found miRNAs that may contribute to 
increased EMT and the invasiveness of CDDP cells. However, these miRNA alterations 
are not necessarily indicative of the causative role of miRNA dysregulation in cancer 
drug resistance development. The ultimate goal of future studies is to address and identify 
these roles during the stepwise acquisition of molecular changes during development of 
drug resistance, among other questions.  Our study thus serves as a roadmap for the 
future analysis of the roles of miRNAs in drug resistance. 
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Table 3.1  miRNA expression profile in MCF-7 and MCF/CDDP breast cancer cells. 
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Figure 3.1.  Hierarchial clustering of the differentially expressed miRNA genes (as 
determined by ANOVA) in the MCF7 and MCF7/CDDP cells.  For each, red color 
denotes high expression levels whereas green means low expression levels Each listed 
miRNA is significantly different (p<0.01) between the resistant and parental cell line. 
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Figure 3.2. Association between DNMT3a and MeCP2 expression and aberrant 
DNA methylation in cisplatin-resistant MCF-7 cells. 
a. Decreased protein levels of DNMT3A and MeCP2 in MCF-7/CDDP cells, as detected 
by Western immunoblotting.  Graph represents a quantitative evaluation of the DNMT3A 
and MeCP2 protein levels in the MCF-7/CDDP cells relative to those in the MCF-7 cells.  
b. Global DNA hypomethylation in the MCF-7/CDDP cells as determined by [3H]dCTP 
extension assay after digestion of genomic DNA with methylation sensitive restriction 
endonuclease HpaII. 
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Figure 3.3. Altered levels of ZEB1 and E-cadherin, and invasive phenotype of 
cisplatin-resistant MCF-7 cells.  
A) Increased levels of ZEB1 and decreased levels of E-cadherin in the MCF-7/CDDP 
cells as detected by immunofluorescence using primary antibodies against ZEB1 (green) 
and E-cadherin (green) and by western immunoblotting.  
B) Increased invasiveness of the cisplatin-resistant MCF-7 cells. MCF-7 and MCF-
7/CDDP cells were plated in invasion chambers. After 48 hours, cells on the bottom side 
of membrane were stained and mounted onto glass slides and mean number of cells in 
four replicates was determined.  
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Figure 3.4.  Levels of MRP1 in MCF-7 cells and MCF-7/CDDP cells. MCF-7 and 
MCF-7/CDDP cells were grown in triplicate. Each line represents a protein extract from 
an independent flask. Top, representative western immunoblot; bottom, a quantitative 
evaluation of the MRP1 protein levels in the MCF-7/CDDP cells relative to those in the 
MCF-7 cells. (*denotes p<0.05). 
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Figure 3.5. miR-345 and miR-7 target multidrug resistance protein 1 (MRP1).  
A) Alignment of the 3‘UTR of MRP1 by miR-345 and miR-7. The original cloning of the 
UTR was based on transcript NM_004996 for the MRP1 gene and the binding regions for 
miR-7 and miR-345 bound at 5346-5368 nTs and 4819-4838 nTs, respectively.  Seed 
regions have been defined as at least 5 Watson-Crick base pairs within the 2-7 
nucleotides of the 5‘ region of the miRNA. Mutant vectors abolished the corresponding 
seed sequeneces at the 3‘ end of the miRNA binding site within the vector. Nucleotides 
depicted in blue represent wild-type seed-interacting sequences. Red nucleotides depict 
mutated regions. 
B) Targeting of the 3‘UTR of MRP1 by miR-345 and miR-7. For the luciferase reporter 
experiments, a vector containing the 3‘-UTR segment of the MRP1 (Abcc1)gene, hsa-
miR-7 and hsa-miR-345 were co-transfected.  Scrambled oligonucleotides and un-related 
miRNA (miR-127) served as controls.  Activity was assayed after 24hours. 
C) Decreased levels of MRP1 24 hours after transfection of MCF-7/CDDP cells with 
miR-7 and miR-345. The MCF-7/CDDP cells were transfected with miRNAs as 
described above and the levels of MRP1 were measured by western blotting.  
D) Increased sensitivity of MCF-7/CDDP to CDDP after transfection with miR-7 and 
miR-345. 
 
72 
 
4.  Doxorubicin and cisplatin resistant MCF-7 cell lines display strikingly similar 
DNA methylation profiles, copy number variation and gene expression patterns 
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4.1  Abstract 
Many chemotherpauetic agents achieve their effect by eliciting extreme genotoxic stress.  
This includes two commonly prescribed chemotherapy drugs cisplatin and doxorubicin. 
Doxorubicin is widely used in curative-intent adjuvant breast cancer therapy. It is an 
intercalator which interferes with topoisomerase function, blocks replication and leads to 
induction of apoptosis. Cisplatin is an alkylating agent that causes crosslinks and 
therefore interferes with cell division. It is used to treat a range of cancers including 
ovarian and breast cancer
4,5
.  
We have previously generated two separate MCF7 cell lines resistant to either cisplatin or 
doxorubicin.  The resistant lines demonstrated ~3-fold faster growth rates, increased 
invasiveness and cross resistance to radiation.  In an attempt to evaluate genome wide 
locus-specific DNA methylation changes and the concomitant gene expression changes, 
we use the Illumina DirectHyb gene expression and Infinium Human Methylation27 bead 
chip assay. We noted a surprisingly congruent global DNA methylation profile between 
the MCF-7/DOX and MCF-7/CDDP lines. Our results show that >50% of the DNA 
methylation and gene expression changes are inversely correlated. Such a strong 
correlation between gene expression and DNA methylation strongly  suggests that 
epigenetic control is important for acquired chemoresistant phenotype.  Furthermore, 
comparative genome hybrization also revealed  a pronounced degree of genome 
instability and highly similar patterns of genome rearrangements in MCF-7/DOX and 
MCF-7/CDDP cells.   
We suggest that the increased instability of the resistant lines may be a consequence of 
the epigenetic dysregulation.  Finally, our data support the notion that acquisition of drug 
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resistance is an epigenetic-regulated process and that certain commonalities exist between 
resistant cells acquired under different selection pressure, thus, explaining phenomenon 
of cross resistance. 
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4.2  Introduction 
Nearly 90% of all recurring breast cancers exhibit multi-drug resistance, increased 
invasiveness, cross resistance to radiation and present a poor prognostic outcome
6
.   This 
drug resistance is the result of several molecular mechanisms including reduced 
intracellular concentrations, altered targets, efficient repair of DNA repair and evasion of 
apoptosis
1,6
.  The acquisition of the resistance has roots in genetic, epigenetic and 
karyotypic changes to the genome.  Although genetic changes likely contribute in some 
instances, the ‗one mutation:one altered protein‘ theory  is too limiting to explain the 
multi-factorial phenotype of drug resistance and especially cross-resistance.  The 
epigenetic and karyotypic theories allow for the robust, wide spread changes that are 
necessary to elicit the broad phenotype and, thus, are likely the major contributing 
chemoresistance mechanism
52
.  The epigenetic theory hypothesizes that drug resistance is 
the result of DNA methylation, histone modifications and/or small, noncoding regulatory 
RNAs while the karyotypic implicates gross chromosomal aberrations as the driving 
force
52,63
.  These theories are not mutually exclusive of each other as the genomic 
instability required by the karyotypic theory requires epigenetic alterations.  The role of 
epigenetics in the acquisition of drug resistance has been described previously
63
.   
 
We have further explored the role of epigenetics through the investigation of two breast 
adenocarcinoma (MCF7) cell lines resistant to cisplatin or doxorubicin.  We uncovered 
the  role that  small, non-coding RNAs play in the drug resistant phenotype by 
demonstrating their influence on over-expression of drug efflux pumps.  Furthermore, we 
have demonstrated a global hypomethylation of in these drug resistant cell lines
21
.  Here 
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we attempt to increase the understanding the role of DNA methylation in the process by 
increasing the resolution of our assay. We hypothesize that drug-resistant cells will 
exhibit a well-defined pattern of DNA methylation at a variety of loci. These changes 
may be linked to the expression of the given loci, thus contributing to the drug resistant 
phenotype.  Furthermore, we believe the hypomethylated genome is responsible for 
diminishing genome stability.   
 
To test our hypothesis we conducted a genome-wide analysis of the locus- specific DNA 
methylation profiles, gene expression and copy number variations in the MCF-7 cells and 
their variants resistant to doxorubicin and cisplatinum.   Here we show that patterns of the  
three measured attributes were strikingly similar in MCF-7/DOX and MCF-7/CDDP 
cells. This prompted us to speculate that epigenetic and/or karyotypic profiles may not be 
unique to particular instances of resistance but rather provide plausible cross-resistance 
markers.  Furthermore, we used our data to describe some of the phenotypic features of 
drug resistance including increased growth rate, diminished cell cycle control and 
reduced apoptosis.   
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4.3  Materials and Methods 
4.3.1  Cell culture 
The MCF-7 cells were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA) and were maintained according to ATCC‘s recommendations. The MCF-
7 drug-resistant variants were established by stepwise selection after prolonged (>6 
months) treatment of MCF-7 cells to increasing concentrations of CDDP (Sigma) or 
DOX at a range of 0.5–25 μM in the medium21. After 6 months of culturing in the 
presence of CDDP or DOX, the IC50 (inhibitory concentration to produce 50% cell 
death) values were 94 and 12 μM of CDDP for the MCF-7/CDDP and parental MCF-7 
cells, respectively; and 24 and 1 μmol/L DOX for the MCF-7/DOX and parental MCF-7 
cells, respectively.  Cells were seeded at a density of 0.5 X10
6
 viable cells per 100 mm 
plate, and the medium was changed every other day for 6 days. Trypsinized cells were 
washed in phosphate-buffered saline and immediately frozen at -80°C for subsequent 
analyses. The experiments were independently reproduced three times, and each cell line 
was tested in triplicate. 
 
Cell growth rates were determined by seeding 2x10
5
 cells in a 10cm culture plate.  Plates 
were photographed every 24 hours for the next 72 hours and cells counts performed on 
four  field of views (n=4). 
 
4.3.2  DNA Preparation and microarray based methylation and CGH analysis 
DNA was collected from cells using the DNA Easy Blood and Tissue Extraction kit 
(Qiagen) according to manufactures protocols.  Briefly, cells were lysed and the liberated 
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DNA was treated with RNAase (Sigma) and adsorbed to silica membranes.  The 
membrane bound DNA was washed with the prescribed buffers and eluted with water.   
 
The collected DNA (500ng) was bisulfite converted using the DNA EZ methylation kit 
from Zymo Research according to manufactures protocol.  This process converts cytosine 
residues on single stranded DNA to thymine residues in the presence of quinine and 
sodium bisulfite.  Methylated cytosines are not a proper substrate for this reaction and, 
therefore, are left unconverted.  Methylation was determined using the Infinium assay on 
the Illumina platform.  Data was collected from the >27, 000 probes represented on the 
HM27 microarray.  These probes contain CpG dinucleotides from selected loci 
throughout the genome.  All steps were carried out according to the manufacture‘s 
specifications and with Illumina supplied reagents.  In short, bisulfite converted samples 
were amplified overnight, fragmented and purified.  The resuspended sample was 
hybridized overnight to the microarray which harboured millions of bead-bound 50-mer 
oligos.  Each interrogated loci is represented by two bead types: a methylated type, ‗C‘ 
remains a ‗C‘; and an unmethylated type, ‗C‘ becomes a ‗T‘.  Hybridized chips were 
washed to remove unbound or non-specific DNA fragments.  The resulting oligo-sample 
hybrid is then extended with a biotin linked dedeoxy cytosine and stained with 
streptividin.  The relative intensity of the unmethylated to methylated bead for each allele 
provides a measure of relative methylation level.   
 
Complete genome hybridization was also performed using the Infinium assay on the 
Illumina platform according to the manufactures protocol.  The chemistry for this assay is 
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identical to what is described above with the exception that beads harbour oligos that 
represent each of the possible base SNP variations for the interrogated locus.  Also, the 
extension of these loci will create a two color signal (red and green).  The relative 
intensities of these colors indicate what base combination is present in the SNP.  Copy 
number variation (CNV) was determined by using contiguous SNP data in an Illumina 
algorithm and comparison to a reference genome
177,178
.     
 
4.3.3  RNA preparation and expression microarrays  
Total RNA was extracted from cells using Trizol reagent and according to the 
manufacturers protocols (Invitrogen).  Extracted RNA was further purified with the RNA 
Easy kit from Qiagen.  This purification step was necessary to remove all traces of 
phenol.  The quality of the resulting RNA was assayed using a bioanalyzer 2100 
(Agilent).   
 
Gene expression analysis was achieved through the whole genome hybrization assay on 
the Illumina platform.  Each line was assayed in quadruplicate.  All practices were carried 
out according to Illumina protocol and using manufacturer supplied reagents.  First, a 
library of cRNA was prepared using the Ambion TotalPrep RNA amplification Kit 
(Invitrogen) and 500ng of input total RNA.  This involved an RT-PCR step followed by 
second strand synthesis.  cDNA was then purified on a silica column and in vitro 
transcription was performed and the resulting cRNA purified again.  For the bead arrays, 
750ng of cRNA was hybridized to the human whole genome bead array chip HT-12v4.  
This array contained >47,000 probes that represent genes included in NCBI ReqSeq data 
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base.  Following overnight hybrization, the microarrays were washed several times.  This 
included a 10 minute, static high stringency (high temperature and salts) wash, five 
minute room temperature wash on an orbital shaker, ten minute wash in 100% ethanol on 
an orbital shaker and a second room temperature wash.  Arrays were blocked for 10 
minutes and stained with a streptividin-Cy3 tag for detection purposes.  Next, arrays were 
washed a final time at room temperature, briefly centrifuged and dried.  The bead arrays 
were scanned using an iScan (Illumina).  Signal data was interpreted with the aid of the 
genome studio (Illumina) software.   
 
4.3.4 Polymerase Fidelity Assay 
A polymerase fidelity assay was performed to observe the relative levels of polymerase 
fidelity between the samples.  This involved placing total protein extracts from the cells 
in a reaction mixture with dNTPs and a fluorescently labelled, primer-template hybrid of 
known sequence.  Samples were run post-reaction on a 20% denaturing polyacrylamide 
gel and visualized using a phosphoimager.  The specifics of the assay are as follows. 
 
The primer/template complex for the assay was prepared by annealing the fluorescein 
amidite (FAM)-labelled 15 bp primer (5‘-6-FAM-TCCCAGTCACGACGT-3‘, PAGE-
purified) to the 30 bp template (5‘-TCATCGAGCATGATCACGTCGTGACTGGGA-3‘, 
PAGE-purified). All components were mixed by pipetting in the following order (on ice): 
Tris-HCl (1M, pH 8.0) = 10 μl, β-Mercaptoethanol (14.3M) = 0.5 μl, BSA (10 mg/ml, 
NEB) = 2 μl, Primer (100μM) = 3 μl, Template (100μM) = 3 μl, and H2O = 183.5 μl for 
a total volume of 200μL. The reaction was incubated for 5 min in boiling water and then 
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allowed to cool to room temperature (20-25°C). The complex was prepared in advance 
and stored at -20°C. 
 
Freshly harvested cells were sonicated in 1X PBS for 10, five second intervals.  Samples 
were placed on ice between intervals to prevent heating.  Following sonication, samples 
were spun down at 13,000Xg for 10 minutes.  Protein levels were determined using a 
Bradford Assay.  70 μg of protein from the crude extract was used immediately in the 
polymerase reaction.  The crude extract was mixed with 2.5 μl of the primer/template 
complex, 2.5uL of  2mM dNTPs, 2.5μl reaction buffer (10x Y+/Tango, Fermentas) and 
water for a total volume of 25μl.  The reaction was carried out at 37 ºC for 15 min in a 
PCR machine, quenched with 50 μl of loading buffer (95% formamide, 50 mM EDTA, 
and 0.05% bromphenol blue), heated to 95°C for 3 min and cooled on ice for 2 min. A 
reaction including Klenow enzyme (NEB buffer 2) in place of a protein extract was used 
as a positive control (ladder). 
 
After quenching, 15 μl of the sample/loading buffer mix was loaded on a 20% 
polyacrylamide gel (20x20x0.075 cm) containing 8 M Urea. Also, 0.5 μl of the 15 bp 6-
FAM-labelled primer was mixed with 2.5 μl of loading buffer and loaded on the 
polyacrylamide gel to serve as a molecular weight marker. Electrophoresis was carried 
out in 1x TBE buffer for ~5 hours at 500 V. Gels were scanned using Typhoon 9410 at an 
excitation wavelength of 88 nm using a 520 BP 40 emission filter, the PMT voltage of 
685 V, at a resolution of 100 μm. Images of scanned gels were analyzed using 
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ImageQuant 5.2 software (Molecular Dynamics). For the adjustment of total values of the 
object outline, the Local Median background correction method was applied    
 
4.3.5  Western blot analysis of protein expression 
The protein levels of Polymerase beta (polβ), epsilon (Polε) and iota (Polι) were 
determined by Western blotting using protocols described previously
21,154,161
.  Polβ 
antibodies (Abcam) were used at a dilution of 1:1000 and probed with anti-rabbit 
secondary at 1:500 dilution (Santa Cruz Biotechnologies).  Polε and Polι antibodies were 
procured from Santa Cruz Biotechnologies and employed at a dilution of 1:500.  Polε 
necessitated an anti-mouse secondary and Polι an anti-goat, both were used at 1:500 
dilution (Santa Cruz Biotechnology).     
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4.4  Results  
4.4.1  Growth rate of resistant cells 
The resistant cells grew ~3-fold faster than the sensitive parental MCF7 line (Fig. 4.1). 
All cells were initially seeded at a density of 2.7x10
3
 cells/cm
2
 and counted every 24 
hours over a 72 hour period, the p-values were calculated for the each resistant line 
relative to the MCF7 parental values.  At the 24 hour time point, cell numbers were: 
5.9x10
3
 (S.E.±126), 1.7x10
4
 (S.E.±238; p<0.001) and 1.6x10
4
 cells (S.E.±593, p<0.01) 
for the MCF7, MCF7/CDDP and MCF7/DOX, respectively.  At 48 hours the cells count 
was: 1.6x10
4
 (S.E.±188cells), 3.4x10
4
 (S.E.±405; p<0.001) and 4.8x10
4
 cells/cm
2
 
S.E.±1442; p<0.01) for the MCF7, MCF7/CDDP and MCF7/DOX, respectively.  Finally 
at 72 hours, cells counts were: 3.3x10
4
 (S.E.±342cells), 1.0x10
5
 (S.E.±1458; p<0.001) 
and 1.2x10
5
 cells/cm
2
 (S.E.±1227; p<0.001) for the MCF7, MCF7/CDDP and 
MCF7/DOX, respectively.  Furthermore, cell morphology and cell-cell interactions 
deviated visibly in both resistant lines relative to the sensitive parent.  In the 
MCF7/CDDP cells display spindly out crops while the MCF/DOX cells seem to prefer a 
equidistant spacing with minimal physical contacts between adjacent cells.  In contrast 
the MCF7 cells display a relatively round cell shape and prefer tight intercellular spacing.  
These differences in morphology have been linked to invasiveness and their implications 
have been discussed in previous chapters.   
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4.4.2  Gene Expression and methylation in the MCF7, MCF7/CDDP and MCF7/DOX 
cell lines 
Microarray analysis using the Illumina platform revealed a total of 1329 and 1344 
statistically significant (p<0.05; 0.5>fold change>2) expression changes in the 
MCF7/CDDP and MCF7/DOX lines respectively (Fig. 4.2A).  Interestingly, 1219 (424 
down— and 795 up regulated) of these changes were common with similar direction and 
amplitudes of changes between the two lines.  The net signal of these genes was ~3-fold 
higher in the resistant lines, thus, indicating a higher level of transcription. 
 
Genome-wide methylation profiles were assayed using the Illumina based Infinium 
microarray.  Again results between the two lines were similar.  Of the 2252 differentially 
methylated loci in the MCF7/CDDP  and 2227 loci in the MCF7/DOX, 2025 were 
common in amplitude and direction between the lines (p,0.05; 0.05>fold change>2) (Fig. 
4.2B).  Of the common loci, 596 were hypomethylated and 1427 hypermethylated 
relative to the parental line.  When comparing total signal values, the MCF7/CDDP and 
MCF7/DOX displayed ~1.3-fold more signal than the MCF7 lines.   
   
There were 123 genes that demonstrated significant changes in both gene expression and 
methylation patterns (Fig. 4.3A).  These genes were grouped into several ontology 
categories including in descending order with respect to the number of genes affected: 
metabolic processes (GO:0008152), nucleic acid metabolism (GO:0006139), 
transcription (GO:0006350), apoptosis (GO:0008219), proliferation (GO:0008283), cell 
cycle regulation (GO:0007049) and cell growth (GO:0016049).  Most genes were binned 
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into metabolic processes and nucleic acid metabolism, 68% and 62%, respectively (Fig. 
4.3B, Table4.1).   
 
Of the 123 genes common between both lines with significant changes in gene expression 
and methylation, 58% had inversely proportionate changes.  These genes obey the 
‗classical theory‘ of increased methylation leading to repressed expression and vice versa 
(represented in quadrant #1 and #3 in Fig.4.3).  37% exhibited an increase in both 
expression and methylation (quadrant #2 of Fig.4.3) while only 4% a decrease in both 
(quadrant#4 of Fig.4.3)—depicting a ‗non-classical‘ model.  In an attempt to explain the 
‗non-classical‘ genes we interrogated the entire genome for copy number variations 
(CNV).  Again our analyses presented a strikingly similar profile between the two 
resistant lines relative to the MCF7 parental line.  Specifically, 20 regions were 
commonly deleted between the two lines, however, none of the ‗non-classical‘ probes 
could be mapped to these regions.  These deleted regions spanned in size from ~2x10
5
 to 
2.5x10
6
, however, this was minuscule in comparison to the ~600 regions displaying 
amplification relative to the MCF7 parental line (Fig. 4.4A).  Interestingly, when we over 
layed the CNV data for only the 123 genes showing changes in gene expression and 
methylation, the resistant lines finally demonstrated some individuality.  Of the 123 
genes, 26% and 35% of the genes did not deviate from the parental copy number in the 
both MCF7/CDDP and MCF7/DOX cells, respectively.  However, ~45%  and 25% were 
increased in MCF7/CDDP and MCF7/DOX cells, respectively.  The opposite was trend 
was true for depleted regions where the MCF7/CDDP had fewer (30%) deletions and the 
MCF7/DOX more (~40%).    
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4.4.3  Polymerase Fidelity 
Global polymerase activity was assayed via a polymerase fidelity assay that measures the 
efficiency and fidelity of single nucleotide incorporations on a known template.  The 
results are presented in figure 4.6.  As the nucleotides are incorporated, bands appear at 
sizes larger than the 15bp primer template substrate.  Exonuclease activity is observed by 
the appearance of bands below the 15bp size.  Relative to the MCF7 line, the resistant 
lines had higher activity, reduced fidelity and diminished exonuclease activity.  In the 
presences of dATP, dCTP and dTTP, a 16 bp band is not expected as the template calls 
for a dGTP incorporation, and interestingly, none of the samples demonstrate any 
appreciable incorporation.  Likewise, in the presence of dGTP, all the samples show a 
healthy 16 base pair band.  However, when dGTP and dATP, are both supplied, the 
resistant cells show heavier bands of incorporation at 16 and 17 bp suggesting a higher 
rate of activity.  Furthermore, the DOX cells appear to continuously incorporate the 
nucleotides beyond the two base pair demands of the template demonstrating a reduced 
fidelity (marked with red asterisks, Fig. 4.6).  Interestingly, the resistant lines tend to 
display fewer and less intense bands at sizes below the initial 15 bp of the primer-
template.  These bands, indicative of exonuclease activity, suggest that the resistant lines 
do not display as much exonuclease activity.  
 
Western blot analysis for specific polymerases (epsilon—ε, beta—β and iota—ι) revealed 
a striking difference between Polε protein expression—reduced to ~0.3 and 0.2-fold 
(P<0.001) in the MCF7/CDDP and MCF7/DOX lines, respectively.  Polβ, an active 
member of the DNA repair protein contingency, was differentially expressed in the 
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MCF7/DOX resistant lines—1.15-fold in the MCF7/CDDP cells and 0.6-fold in the 
MCF7/DOX.  However, with a P>0.1 for the MCF7/CDDP  line, only the DOX cells 
were significantly altered (p<0.01).  The translesion synthesis Polι was significantly 
increased in both lines albeit to a much higher extent in the DOX lines—1.7 (p<0.0001) 
and 3.94-fold (p<0.001) Fig. 4.5.   
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4.5  Discussion 
The astonishing growth rates of the resistant cell lines prompted us to make several 
speculations.  1) These cells spend most of the time in S-phase replicating DNA and, 
thus, should have an increased polymerase capacity to achieve this feature of accelerated 
growth.  2) Any stalling for cell cycle checkpoints or damage repair is prevented.  3) 
Apoptosis is rare.  4) A massive level of genomic instability must exist.   
 
A polymerase fidelity assay indicated that the resistant lines had a higher activity and, in 
the case of DOX cells, a lower fidelity of incorporation.  This suggested that perhaps 
DNA polymerases responsible for bypassing damage or repairing damage would show 
altered levels of expression.  Indeed, this was the case for Polι, a polymerase involved in 
translesion synthesis that localizes to stalled transcription machinery and quickly 
incorporates bases at highly distorted and uninformative templates
179,180
.  DOX cells 
showed ~3-fold (p<0.01) increase in Polι protein expression while the MCF7/CDDP cells 
showed ~1.7-fold increase.  On the other hand, the MCF7/DOX cells experienced a 0.6-
fold change while MCF7/CDDP did not display a significant change.  The differences in 
these expressions may be explained by the mechanism of action for each drug.  Polβ is a 
high fidelity enzyme involved in DNA repair.  It‘s over expression is linked to genomic 
stability and cisplatin resistance in ovarian and colorectal cancer cell lines
181,182
.  
Interestingly, Polβ was repressed in the MCF7/DOX lines suggesting that it plays less of 
a role in circumventing the effects of the drug.  This may be due in part to the mechanism 
of action.  Doxorubicin does not directly damage DNA, but rather acts as a physical 
interference to the transcriptional machinery—indicating a higher requirement for Polι.  
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Cisplatin exposure does result in direct DNA damage that would present as a suitable 
substrate Polβ activity.  It is possible that due to selective pressure during the six months 
of drug exposure, each line sustained these beneficial alterations.   
 
In addition, we assayed for the presence of Polε, one of the three major polymerases 
involved in replication.  Polε possesses exonuclease activity and an added responsibility 
in DNA damage repair.  Polε protein was down regulated ~0.2 and 0.3-fold in the 
MCF7/CDDP and MCF7/DOX cells, respectively.  Interestingly, the resistant lines each 
displayed a considerably reduced exonuclease activity relative to the MCF7 parental 
lines.  It is possible that with such low levels of Polε protein, global exonuclease activity 
was depressed.  This would further indicate lower fidelity in the resistant lines as 
exonuclease activity is usually employed in reversing erroneous incorporation events.  
Combined with the high rate of incorporation (high growth rate), it is reasonable to 
expect that misincorporations are common and rarely reversed.   
 
Since leading strand production relies heavily on Polε it is difficult to explain the 
extremely low protein levels.  The rapid growth rate of these cells mandates expedited 
replication of the genome, however, one would expect a severe impairment of replication 
rates with such low Polε levels.  Although mammalian Polε is not well investigated, 
studies into the budding yeast enzyme have revealed that the polymerase and exonuclease 
activity of Polε is nonessential as catalytically-incapable mutants are proficient at 
replication and repair
183
.  Therefore, it is possible that the other polymerase members, for 
example the over expressed Polι, are capable of carrying the burden of rapid DNA 
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replication in the drug resistant cells.  Finally, the Polε gene experienced ~2.5-fold 
hypermethylation in the resistant lines suggesting that the mechanism of repression may 
be epigenetic in nature. 
 
Even in the absence of Polε, the remaining polymerases may increase their activity, thus, 
allowing the resistant cells to maintain an increased rate of activity.  For example, Wrnip 
is an ATPase that is known to interact with polymerase delta increasing its activity up to 
5-fold.  It likely achieves this by acting as a modulator for initiating or restarting stalled 
Polδ184.  Gene expression arrays demonstrated a ~2-fold increase in Wrnip expression 
while, methylation arrays demonstrated a 0.4-fold reduction of regulation.   
 
Regulation of the cell cycle appears to be drastically impaired in the resistant cell lines as 
the cells are continuously replicating and dividing with virtually no stalling for important 
check points in the cell cycle.  Key proteins involved in controlling the cell cycle are 
severely deregulated in the resistant lines.  For example, CDK2, which is responsible for 
promoting the movement from G1 into (and then through) S-phase demonstrates a down 
regulation of 0.15-fold in expression with a concomitant 4.3-fold increase in methylation.  
This suggests that the deregulation of this gene is epigenetic in nature.  If CDK2 –cyclinE 
and CDK2-cyclinA complexes are the driving force of S-phase, it would be expected that 
a reduction in the availability of CDK2 would result in a G1-S phase halt. Clearly this is 
not the case in the resistant lines.  It is possible that another protein plays a redundant role 
for CDK2 in allowing progression through the cell cycle as CDK2 knockout mice are 
perfectly viable
185
.  Interestingly though, these mice do display a slower entrance into S-
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phase.  We have postulated two possible reasons for the diminished CDK2 capacity.  
First, if one assumes that these cell lines have maintained some self-governing 
mechanism, it is possible that the large repression seen in the resistant lines is a futile 
attempt to slow and control S-phase.  Second, we have previously shown (chapter 2) that 
Rb is practically non-existent in the resistant cell lines: Rb is a substrate for Cdk2 
activity.  With the loss of Rb, any requirement for CDK2 to drive the cell into S-phase 
via the relief of the oppressive nature of Rb is also lost.  Therefore, the diminished CDK2 
expression may have been relatively inconsequential relative to the loss of Rb.  
Additionally, the lack of CDK2 may partially explain the high radio-resistance observed 
previously in these lines
71
.  Radiation induced damage is signalled through the ATM 
pathways to CDC25 which acts as repressor of CDK2 activity, thus, preventing S-phase 
progression.  Perturbations in the CDK2-CDC25A pathway have been linked to a more 
radio-resistant DNA synthesis that allows cells to continue replication following ionizing 
radiation
186
.   
 
A similar ambiguity arises with the expression of the suppressor of cytokine signalling 
gene (SOCS1).  SOCS1 appears to function exclusively as an anti-proliferative agent yet 
it seems impotent in the resistant lines.  Again, this expression appears to be 
epigenetically controlled as the ~6-7-fold higher expression in the MCF7/CDDP  and 
MCF7/DOX lines correlates with a reduction of <0.1-fold in methylation.  Interestingly, 
aberrant SOCS1 hypermethylation is a common mark of cancer cells that imparts an 
increased proliferative capacity
187
.  Similar to the CDK2 down regulation, the increased 
SOCS1 signalling seems counterintuitive to the observed phenotype.  Although one could 
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speculate that it is another futile attempt to slow down the growth rate, this begs the 
question of why we do not see a ‗purposeful‘ demethylation in normal tumours?  Why 
should the more deviated cells employ such a level of regulation when the less deviated 
precursors do not?  As is the case with CDK2, the downstream targets of SOCS1 (the 
STAT transcription factors) may be altered or non-existent themselves, thus, negating 
any effect that SOCS1 would normally impart.   
 
Simply put, cell growth rate is a balance between proliferation and apoptosis.  Besides the 
polymerase activity described above, our data have indicated several mechanisms that 
may contribute to the unchecked growth potential of the resistant cells including 
diminished apoptosis and altered DNA damage repair.  For example, our 
expression/methylation screen revealed an increase in the expression (~5-fold expression, 
p<0.001; ~2.5 fold methylation, p<0.01) of Pim2, which acts as an anti- apoptotic 
protein.  Through the phosphorylation of BAD, Pim2 is able to reverse BAD-induced cell 
death
188
.  Pim2 represents an example of the ‗non-classical‘ relationship between 
methylation and gene expression (i.e. both showing changes in the same direction).  This 
scenario will be discussed below.  Another example is provided by Fen1 an endonuclease 
responsible for the removal of the damaged strand during BER with reduced expression 
(~0.5 fold expression, p<0.01; 3.5-fold methylation, p<0.01)
189
.  It does not appear as 
though the resistant cell lines recognize any deterrent to growth and, thus, likely do not 
attempt any repair.  Therefore, reduced expression of a DNA repair protein such as Fen1 
is a feasible scenario.  Less feasible is the fact that Fen1 also has a role in Okazaki 
fragment processing which requires it to interact with PCNA and Polδ on the lagging 
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strand
190
.  It is possible that due to the extra demand on Polδ the presence of Fen1 may be 
counterproductive to an expedient replication and, therefore, its reduced expression may 
favour the increased replicative rate of the resistant cells.  However, this scenario 
demands an alternative processing mechanism for the high number of Okazaki fragments 
that must be produced in these cells
190,191
. Interestingly, Fen1 also has a direct role in 
promoting genomic instability.  Microsatellite stability and telomere maintenance are 
both dependent on Fen1 activity
192,193
.  Therefore, the reduced Fen1 profile is congruent 
with (and may even contribute to) the massive instability observed in these cells the 
observed phenotype of the cells. 
 
As depicted in Figure 4.2, the correlation between methylation and gene expression does 
not always exhibit the ‗classical model‘.  Of particular interest was the category with 
increased methylation and expression that account for nearly 40% of the changes of the 
altered in both (gene expression and methylation) pool.  It is possible that probes in this 
group may arise from the amplified parts of the genome.  The increased gene copy 
number may account for the increased expression despite the increased methylation.  For 
example, figure4.4 illustrates that chromosome 6 is almost entirely, duplicated in the 
resistant lines.  Of the approximately 1200 genes with altered expression levels, 73 are on 
chromosome six and 57 (of the 73) demonstrate increased expression.  With respect to 
methylation, the resistant cell lines have 186 loci on chromosome six with a methylation 
pattern that deviates from the MCF7 parent.  120 of these loci are hypermethylated.  This 
scenario allows for a plausible explanation of the nearly 40% ‗non-classical‘ model of 
expression and methylation.  Perhaps increased copy numbers lead to increased gene 
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expression, the increased amount of sequence may also be a target of methylation events, 
however, these events are insufficient at reducing the higher expression.     
 
Qualitatively speaking, CNV gains account for the majority of the chromosomal 
aberrations.  Although we have not officially investigated the physiological impact of 
each of these gains, we hypothesize that they may have a major impact on the observed 
phenotype.  Furthermore, these changes provide support to the karyotypic hypothesis of 
acquisition of drug resistance and occur in conjunctions with massive epigenetic 
alterations. 
 
Although methylation has a well described role in controlling gene expression, it has 
another responsibility in maintaining genomic stability.  The comprehensive methylation 
profile we achieved through the use of microarray technology suggested that as a whole 
the genome of the resistant cells was hypermethylated—~1.3-fold higher signal in the 
resistant cell lines, however, our previous assay of global methylation via the cytosine 
extension assay revealed a hypomethylated genome.  This discrepancy may lie in the 
biased focus of the microarray.  Probes on the bead array are designed mainly towards 
known CpG islands in promoter regions, where as the cytosine extension assay 
presumably treats CpGs throughout the genome indiscriminately.  Taken together, it is 
plausible that the hypomethylation seen in the extension assay results from a massive 
demethylation of non-transcribed or gene poor regions such as centromeres, telomeres 
and mobile elements; regions that are not well represented on the bead array.  As such, 
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we would expect a large increase in chromosomal aberrations and anueploidy which was 
indeed the case (as described by the results of the CNV analysis).   
 
This body of work has provided information into the epigenetic profile of two drug 
resistant lines and the possible consequences of such gross dysregulation.  MCF7 cells 
resistant to either cisplatin or doxorubicin display growth rates ~3-fold larger than the 
parental line, increased invasiveness and cross resistance to radiation treatment.  
Investigation into the loci specific methylation patterns between the two resistant lines 
revealed a large deviation from the parental MCF7 cells.  The altered methylation status 
was inversely proportional to gene expression greater than half the time, explaining, at 
least partially, the multifaceted phenotype frequently observed in drug resistant tumours.  
We also detailed a scenario where differential methylation patterns are related to 
chromosomal abnormalities.  Data from our screens suggest that the resistant cells 
display altered ratios of polymerase, avoid cell cycle checkpoints, have reduced repair 
activity and evade apoptosis.  Finally, and perhaps most importantly, we revealed that the 
molecular characteristics of the two different drug resistant lines is strikingly similar.  
Both changes in methylation, gene expression and chromosome aberrations were 
practically identical between the two lines suggesting that the mechanism leading to 
acquisition to drug resistance may have common, predictable characteristics regardless of 
the drug treatment.  This provides promise for developing useful diagnostic and 
prognostic biomarkers.  It will be important for future studies to elucidate the most 
proximal events in the acquisition of drug resistance.    
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Table 4.1.  Selected genes demonstrating altered gene expression and DNA 
methylation profiles in the MCF7/CDDP and MCF7/DOX drug resistant lines 
relative to the sensitive, parental MCF7 line. 
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    Figure 4.1.  Drug resistant cell lines demonstrate a higher growth rate. A) MCF7, 
MCF7/CDDP and MCF7/DOX cells photographed 24, 48 and 72 hours post seeding.  All 
plates were seeded with equal density (2x105 cells/ 10mm plate) B) Growth rate curve of 
the parental and resistant lines.  The resistant cells grow nearly 3-fold faster than the 
MCF7 cells. 
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Figure 4.2.  MCF7/CDDP and MCF7/DOX resistant lines demonstrate similar 
patterns of gene expression and differential methylation.  A) 1219 genes displayed 
significant (fold change>2; p<0.05) in both the MCF7/CDDP and MCF7/DOX lines (785 
up regulated and 424 down regulated).  B)  Genome wide locus specific methylation 
analysis revealed 2025 loci with methylation patterns significantly different from the 
MCF7 parental line (1427 increased methylation and 596 down methylated; fold 
change>2, p<0.05).   
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Figure 4.3.  The majority of changes in gene expression that are opposite in 
direction of change in methylation status.  A) 123 genes demonstrated significant 
change in both gene expression and methylation levels in both lines. Data points in 
quandrant #1 and #3 represent an expected relationship of inverse proportionality 
between the expression and methylation result (‗classical model‘).  Points in quadrant #2 
and 4 demonstrated directly proportional changes (‗unclassical model‘). B) The 123 
genes group into several ontology processes.    
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Figure 4.4.  Resisatnt lines display many common CNV alterations, mostly gains. 
 CNV in MCF7/CDDP and MCF7/DOX cell lines relative to the MCF7 parental line 
(continuous coordinates). Legend denots copy numbers of the loci. 
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Figure 4.5.  Drug resistant cell lines experience higher polymerase activity, lower 
fidelity and reduced exonuclease activity.  A)  The primer template construct used to 
measure endogenous polymerase activity.  B)  Endogenous polymaerase activity is 
observed by resolving reaction volume via 20% PAGE.  All dNTPS represents the 
continuum of double starnded-template molecule produced in the presence of all dNTPS; 
ladder -template extension with  Klenow fragment; primer/template – the fluorescently 
labelled 15 base pair (bp) substrate available for polymerase activity.  Bands larger than 
15 bp represent incorporations while bands beneath 15 bp are indicative of exonuclease 
activity.  C)  MCF7/CDDP and MCF7/DOX cells experience less exonuclease activity 
and higher levels of base incormporation (including mis-incorporated nucleotides). 
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Figure 4.6.  MCF7/CDDP and MCF7/resistant cell lines display distorted expression 
levels of DNA polymerases.   Western blotting revealed a decrease in the DNA repair 
polymerase enzyme polymerase β in the MCF7/DOX line only while the translesion 
synthesis polymerase ι was significantly increased in both resistant lines.  DNA 
polymeraseε, one of three polymerases involved in DNA replication, was severely 
depressed in both lines. (*** denotes p<0.001) 
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5.  Conclusion and Future Directions 
 
This work has attempted to evaluate what role epigenetic dysregulation plays in the drug 
resistant phenotype.  The results of this work are several fold.   
 
First, we have indicated that the microRNA profile of drug resistant cells is largely 
different from the parental line.  Many of the dysregulated microRNAs have previously 
described roles in regulation proteins involved in cell cycle regulation, proliferation and 
apoptosis.  We identified novel functions for three of the dysregulated microRNAs—hsa-
miR-451, hsa-miR-7 and hsa-miR-365, in drug efflux.  Drug efflux pump proteins MDR1 
and MRP1 are greatly over expressed in the MCF7/CDDP  and MCF7/DOX lines, 
respectively.  We demonstrated that this over expression is at least in part to under 
expression of the above mentioned microRNAs.  Through ectopic expression, we were 
able to partially recover sensitivity to the cisplatin or doxorubicin drugs—a result with 
therapeutic potential
70
. 
 
Second, we have illustrated a massive dysregulation in the methylation profile between 
the resistant and sensitive cell lines.  In this, we describe a scenario of massive epigenetic 
dysregulation that >50% of the time impacts transcriptional outcome and, therefore, 
explains, at least in part, the phenotype of the MCF7/CDDP  and MCF7/DOX resistant 
cell lines.  The drug resistant phenotype typically displays multiple different 
characteristics.  Explanation of this observation can prove difficult from a mutation-
centric point of view
52
.  The wide range of methylation and concomitant gene expression 
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on our results provides a good explanation of the underlying mechanism of drug 
resistance.   
 
Third, the drug resistant phenotype coincides with a large level of genomic instability.  
Although the design of this experiment did not allow us to determine whether this is a 
cause or consequence of the resistant phenotype, it demonstrated that, similar to the 
epigenetic dysregulation, karyotypic alterations explain the wide phenotype
52
.   
 
Unfortunately, the work was designed around an end point that provided us with cells so 
drastically different from the parental line that it is arguable as to whether they still 
qualify as MCF7 cells.  However, it did provide the striking demonstration that cells 
exposed to two different drugs with different modes of action can acquire drug resistance 
with an almost identical epigenetic and molecular profile.  This alone suggests that the 
acquisition of drug resistance may involve predictable events or display particular 
characteristics that could act as biomarkers or prognostic tools
1,70
.   
 
In the future, it will be important to compare the results of this study to those seen in 
resistance to another class of drugs, for example taxanes or non-mutational, targeted 
therapies.  Do the same epigenetic changes occur during acquisition of resistance to other 
types of drugs? It will also be important to further investigate the acquisition of resistance 
in the MCF7/CDDP  and MCF7/DOX cells described here.  Specifically, it would be 
interesting to perform the selection again and look at epigenetic profiles earlier on during 
the selection process as it is likely the majority of the characteristics observed here are 
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distal events.  We would like to know what the most proximal events that we can observe 
are.  How early are they observable?  Recently, it was shown that methylation patterns 
are extremely plastic and that experiments performed with a single end point do not 
accurately demonstrate a level of persistence (Personal Communication, C. Klein).  Thus, 
it is possible that our one-point-in-time measurement does not accurately convey the true 
frequency or magnitude in changes. 
  
Finally, it is necessary to investigate the basic cytogenetics of the described lines.  We 
were surprised at how different the lines behaved from their parental source, however, the 
experiment had been designed to gain molecular knowledge and, thus, the more historical 
experiments were not originally planned.  Our molecular data, both the methylation and 
CNV analysis, suggest a plethora of massive chromosomal aberrations.  This begs two 
questions: first, how do these cells survive with such a distorted genome, and; second, is 
it possible that the gross rearrangements of the chromosomes are not random but rather a 
specific, predictable combination that provides unparalleled survival capacity?   
 
Just as only particular chromosomal trisomys allow for a viable embryo, it is possible that 
there is a narrow combination of karyotypes that would permit survival and even fewer 
that would allow for increased fitness at survival
52
.  Thus, although the genomes of the 
resistant cell lines are severely distorted, perhaps they have achieved one of a few unique 
combinations of abberations that confer the added benefit of drug resistance
194
.  This 
hypothesis allows one to explain the remarkable similarity in molecular changes (miR 
expression, DNA methylation patterns and gene expression) observed between the two 
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different lines created out of prolonged exposure to different drugs.  It will be necessary 
to test this hypothesis by profiling drug resistant lines achieved through exposure to even 
more unrelated (non-genotoxic) drugs.  If true, one would expect to see a similar level of 
congruency between drug resistant cells in general.
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